Enhanced Therapeutic Potential of Preactivated Mesenchymal Stromal Cells and Their Secretory Factor Stanniocalcin-1 in Models for Acute Injuries and Inflammation by Mohammadipoor, Arezoo
  
ENHANCED THERAPEUTIC POTENTIAL OF PREACTIVATED 
MESENCHYMAL STROMAL CELLS AND THEIR SECRETORY FACTOR 
STANNIOCALCIN-1 IN MODELS FOR ACUTE INJURIES AND 
INFLAMMATION 
 
A Dissertation 
by 
AREZOO MOHAMMADIPOOR 
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Chair of Committee,  Darwin J. Prockop 
Committee Members, Ryang Hwa Lee 
 Carl A. Gregory 
 Fei Liu 
 Thomas J. Bartosh 
Head of Department,  Van G. Wilson 
 
 
 
August 2015 
 
 
 
Major Subject: Medical Sciences 
 
 
 
Copyright 2015 Arezoo Mohammadipoor 
  ii 
ABSTRACT 
 
There has been significant interest in the therapeutic potential of the adult 
stem/progenitor cells from bone marrow called multipotent mesenchymal stromal cells 
(MSCs). Signals from injured tissues activate MSCs to secrete beneficial factors and 
contribute to immune/inflammatory modulation and tissue healing. In order to enhance 
the therapeutic potential of MSCs hanging drop culture method was used to preactivate 
the cells in vitro and eliminate the lag period required for their activation in vivo. 
Stanniocalcin-1 (STC-1) is a potent anti-inflammatory and anti-apoptotic protein 
secreted from activated MSCs and has been considered as a substitute for MSCs in 
several disease conditions; therefore, the effects of STC-1 were studied on monocyte fate 
in vitro and in a mouse model of ischemic myocardial injury.    
Aggregated MSCs in hanging drops were self-activated to produce several 
therapeutic factors such as anti-inflammatory protein STC-1 and TNFα stimulated 
gene/protein 6 (TSG-6). MSCs dissociated from spheroids were also smaller than MSCs 
from standard 2 dimensional cultures, and as a result, larger numbers of them trafficked 
through the lung of mice after intravenous administration. Notably, spheroid MSCs were 
more effective than MSCs from standard cultures in suppressing inflammatory responses 
in a co-culture system with activated macrophages and in a mouse model of peritonitis. 
The data suggest enhanced therapeutic potential of spheroid MSCs for diseases caused 
by unresolved inflammation. Treatment with STC-1 reduced expression of CD14, a co-
receptor for toll-like receptors, in differentiating monocytes/macrophages and 
suppressed the inflammatory responses of the cells to endotoxin. Administration of STC-
1 also reduced CD14 expression in monocytes stimulated with various danger signals 
and in hearts of mice after myocardial infarction. These findings may explain the 
observed decreases in cardiac inflammation following myocardial infarction, and the 
improvements in ejection fraction and infarct size. The results suggest that STC-1 is a 
promising therapy to protect the heart and other tissues from ischemic injury. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
I.1 Multipotent Mesenchymal Stromal Cells: Characteristics and Therapeutic 
Potential 
There has been significant interest in the therapeutic potential of the adult 
stem/progenitor cells from bone marrow initially referred to as colony forming units-
fibroblasts (CFU-Fs), then as marrow stromal cells and subsequently as mesenchymal 
stem cells and currently as multipotent mesenchymal stromal cells (MSCs). Each of the 
names reflect a different property or function of the cells. Marrow-derived MSCs are 
easy to isolate and expand in culture. These cells divide well in culture and their progeny 
are further capable of differentiating into one of several mesenchymal phenotypes such 
as osteoblasts, chondrocytes, and adipocytes. In addition, MSCs secrete a variety of 
cytokines and growth factors that have both paracrine and autocrine effects on different 
physiological and pathological processes [1-3]. 
 
I.1.1. Isolation and characteristics of bone marrow-derived multipotent mesenchymal 
stromal cells 
Marrow stromal tissue contains variety of cells plus extracellular matrix to 
support the hematopoietic cells and influence their proliferation and differentiation. In 
addition to adipocytes, osteoblasts, endothelial cells and macrophages; marrow stromal 
cells include spindle-shaped cells, previously known as fibroblast-reticular cells, which 
form the reticular tissue and possess distinct osteogenic potencies [4,5]. The stromal 
fibroblast-reticular cells were considered histogenetically to be independent of the 
hematopoietic cells. These cells were shown to contain recipient genotypes in the 
radiochimeric bone marrow, while macrophages and hematopoietic and lymphoid cells 
were replaced by donor cells. In semisyngeneic heterotopic transplants of bone marrow, 
fibroblast-reticular cells were also found to retain their donor origin independent of host 
hematopoietic cells [4-6]; thus, these cells were considered responsible for the 
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specificity of the microenvironment. Moreover, developments in the in vitro culturing 
system led to better understanding of how the signaling pathways played unique roles 
within the microenvironment of the marrow and characterized the marrow cells within 
the hematopoietic niche. 
In early attempts to culture bone marrow, Friedenstein and colleagues revealed 
that a small fraction of marrow stromal cells adhered to culture dishes. Friedenstein 
observed morphological similarity of the adhered cells to the spindle-shaped fibroblast-
like cells that formed the stroma of marrow [6,7]. Since these cells expanded as single-
cell derived colonies in monolayer cultures, he named them CFU-Fs. The clonal origin 
of the fibroblastic colonies was confirmed, later, using thymidine labeling, time-lapse 
photography and chromosome markers [8,9]. The cells from the colonies were easily 
maintained in vitro. In addition, they were shown to differentiate into bone after 
retransplantation of diffusion chambers under kidney capsules [4,7]. Further studies 
showed that multipotent bone-marrow-derived colony forming stromal cells were 
developmentally originated from mesenchymal tissues and, therefore, were named 
mesenchymal stromal cells (MSCs) [10]. 
During the primary cultures of whole bone marrow aspirate, the hematopoietic 
fraction has been shown to disappear mostly within 2 to 3 weeks. The non-hematopoietic 
plastic-adherent compartment of bone marrow consists of a variety of heterogeneous 
populations of cells; thus, since 1990 several groups of investigators have attempted to 
prepare more homogeneous populations [2,11]. In addition, several multipotent MSC-
like cells were recovered from various tissues, particularly from human adipose tissue, 
umbilical cord blood, placental tissue, and even exfoliated deciduous teeth [12-15]. 
Because various methods are used in different labs to isolate, expand, and characterize 
MSCs and MSC-like cells, interpretation and comparison of their outcomes is difficult. 
Therefore, the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy proposed minimal criteria to define human MSCs. First, the 
cells must be plastic-adherent when maintained in standard culture conditions. Second, 
MSCs must express CD105, CD73, and CD90 surface antigens when analyzed by flow 
  3 
cytometry. In addition, they must lack expression of the following hematopoietic 
antigens: CD45, CD34, CD14 or CD11b, CD79a or CD19, and human leukocyte antigen 
(HLA)-DR. Thirdly, MSCs must differentiate into osteoblasts, adipocytes and 
chondrocytes in vitro. While these criteria will most likely require modification as new 
knowledge unfolds, the standardization of the minimum criteria for MSC classification 
will serve to facilitate the exchange of data among investigators [16]. 
Typically, in order to isolate adult human bone marrow-derived MSCs the bone 
marrow aspirates are taken from the iliac crest of normal adult donors. Discontinuous 
density gradient centrifugation is mainly used to separate the mononuclear layer of bone 
marrow aspirates, which contains the MSCs. The mononuclear cells are then cultured in 
the plastic based culture dish. After 24 hours, non-adherent cells are discarded and 
remaining adherent cells are expanded in α-minimal Eagle’s medium (αMEM) 
containing fetal bovine serum (FBS) or fresh human serum [4,17-19]. In some cases, 
MSCs are purified from mononuclear layer based in the expression of the primitive MSC 
marker, STRO-1; otherwise, the cells from passage one or higher are used for 
characterization [20]. After an initial lag phase for MSCs to proliferate in culture, the 
cells divide rapidly, with a donor-dependent average initial doubling time of 12 to 24 
hours. Initial plating density is another factor for MSC proliferation rate. As the cultures 
approach high density, MSCs enter a stationary phase and transform from a spindle-like 
morphology to a larger, flatter phenotype; therefore, for expansion purposes the cells are 
maintained below their confluency level. Typically, the MSCs recovered from a 2-mL 
bone marrow aspirate can be expanded 500-fold over about 3 weeks resulting in 
theoretical yield of 12.5 to 35.5 billion cells. The cells generally retain their 
multipotentiality for at least 6-10 subsequent passages [19]. Since MSCs could be easily 
isolated from adult bone marrow aspirates or other sources and are rapidly expanded in 
regular monolayer culture through 30 or more population doublings, the cells could offer 
broad therapeutic implications for a variety of diseases. 
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I.1.2. The roles of mesenchymal stromal cells in hematopoiesis  
One of the primary roles for marrow-derived MSCs was proposed to be the 
involvement of those cells in the hematopoietic niche. Confluent cultures of MSCs were 
shown to be effective feeder layers for the culture of hematopoietic stem cells (HSCs). 
MSCs were found, subsequently, to influence all stages of hematopoiesis through 
establishing distinct microenvironments in part by production of regulatory 
macromolecules. The extracellular matrix molecules synthesized by MSCs include 
interstitial type I collagen, fibronectin, and the type IV collagen and laminin of basement 
membranes in cultures. MSCs also secrete cytokines in culture, the most important of 
which appear to be interleukin-1 (IL-1), IL-7, IL-11, stem cell factor (c-kit ligand), 
colony-stimulating factor–1 (CSF-1), granulocyte-macrophage-CSF (GM-CSF), and 
macrophage-CSF (M-CSF). These macromolecules could provide molecular signals to 
modulate mitotic, metabolic, and or development states of neighboring cells. Also, 
marrow-derived MSCs were shown to dynamically respond to environmental 
components resulting in modulation of their own mitotic, metabolic, and or 
developmental activity [10,21-24]. The niche role of MSCs was observed in vivo as 
well. Islands of hematopoiesis formed within the ceramic cubes seeded with human 
MSCs, which were transplanted subcutaneously into immunodeficient mice [25]. 
Moreover, this role was supported in clinical trials when autologous MSCs were 
expanded ex vivo and then infused in breast cancer patients. MSCs were shown to hasten 
the recovery of the hematopoietic system after bone marrow transplants [26]. Together, 
these observations demonstrated that the primary role of the cells is to form niches for 
HSCs [3]. 
 
I.1.3. Therapeutic potential of multipotent mesenchymal stromal cells 
I.1.3.1. Engraftment and differentiation paradigm  
Friedenstein et al. originally reported that MSCs became mineralizing cells or 
chondrocytes in vitro and in vivo [9]. Further studies confirmed that isolated marrow-
derived MSCs were capable of differentiating into multiple cell lineages, including bone, 
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fat, tendon and cartilage [9,10,27]. Also, several reports suggested that under specific 
experimental conditions MSCs could differentiate into skeletal and cardiac muscle, 
hepatocytes, glia and neurons [28-35]. Although the exact mechanisms of MSC 
differentiation are not fully understood, multipotent MSCs have been proposed to repair 
injured tissues by engraftment and differentiation. This paradigm was supported by early 
observations that local administration of MSCs improved bone repair [36]. Other studies 
also determined that MSCs administered to animals, either locally or systemically, could 
home to multiple tissues and improve tissue healing [37-39]. These observations led to a 
few clinical trials using MSCs in children with severe osteogenesis imperfecta [40] and 
children with severe lysosomal storage diseases [41]. Notably, minimal adverse effects 
were detected after administration of MSCs; one of the children developed a mild 
allergic reaction to FBS in which the MSCs were expanded [40]. The promising results 
from these experimental studies and clinical trials encouraged investigators to further 
examine the long term engraftment and differentiation potential of MSCs in several 
settings [3].   
Numerous reports described functional improvements after administration of 
MSCs in models for human diseases such as osteogenensis imperfecta [38], stroke [42], 
myocardial infarction [43], acute kidney injury [44], and diabetes [45,46]; however, 
series of technical challenges limited validating engraftment of MSCs and thus 
influenced the interpretation of the outcomes of those studies. For instance, the available 
tracking methods used to follow MSC differentiation in vivo produced unidentifiable 
artifacts. In addition, species differences in characteristics and behaviors of MSCs 
created a significant experimental barrier [3]. Moreover, some of the observations from 
the studies on the fate of administered MSCs in vivo were inconsistent with the 
engraftment and differentiation hypothesis. In fact, after local administration of MSCs 
into animals the majority of cells were reported to disappear within a few weeks [47-49]. 
Observations with whole body imaging techniques also revealed that most MSCs 
became trapped in the lungs after intravenous (i.v.) infusions into rodents [50]. Lee and 
colleagues (2009) employed quantitative polymerase chain reaction (PCR) assay for 
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human Alu sequences to track tissue distribution of MSCs after i.v. infusion. They 
demonstrated that all of the MSCs were cleared from the circulation within 5 minutes of 
infusion. Most of the cells were recovered in the lungs. MSCs in the lungs disappeared 
with a half-life of about 24 hours and the remaining trace amounts of the cells were 
detected in brain, heart, liver, spleen, and kidney [51]. Interestingly in some disease 
models the medium conditioned (CM) by MSCs in cultures was reported to be as 
effective as the cells themselves [52,53]; therefore, all these observations indicate that in 
many situations MSCs could repair injured tissues and improve functions without 
significant engraftment or differentiation.  
I.1.3.2. Crosstalk paradigm 
Because the engraftment and differentiation paradigm failed to explain all of the 
reparative effects of administered MSCs in vivo, other paradigms were proposed. MSCs 
were shown to express a distinct cytokine profile to maintain HSCs in a quiescent state 
as part of the stromal-cells physiological niche. Interestingly, several investigators 
observed that variety of stimuli could alter the profile of MSC cytokine expression to 
promote proliferation, differentiation, and migration of HSCs. Subsequently, others 
reported the crosstalk between MSCs and injured cells in which signals from injured 
cells or MSCs activated other cells to alter the expression of large arrays of genes 
[2,3,54,55]. For instance, Ohtaki and colleagues (2008) reported that local injection of 
human MSCs into the hippocampi of mice following transient cerebral ischemia, 
reduced neuronal death and improved the neurological deficits. Human-specific 
microarrays of RNA from hippocampi demonstrated that in the injured brain, the 
expression of genes involved in modulation of immune and inflammatory responses 
were increased in human MSCs. Assays of the same RNA on mouse-specific 
microarrays revealed that the presence of the human MSCs modulated expression of 
mouse genes involved in immune responses to the ischemic environment [48]. More 
evidence of crosstalk was observed between MSCs and multiple myeloma cells [55]. Co-
culture studies demonstrated that signals from the myeloma cells stimulated the MSCs to 
increase secretion of IL-6. IL-6 was then shown to stimulate the proliferation of 
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myeloma cells. At the same time, the myeloma cells secreted high levels of Dkk-1, an 
inhibitor of Wnt signaling. DKK-1 in turn, inhibited MSCs from differentiating into 
osteoblasts [54]. The dynamic and transient crosstalk between MSCs and injured tissues 
was suggested as a new paradigm to explain some of the beneficial effects of MSCs in 
vivo. Based on the crosstalk theory, MSCs respond to the injured tissue and enhance 
tissue repair via different mechanisms such as promoting endogenous tissue 
regeneration, modulation of immune and inflammatory responses, and reduction in cell 
death [2,3,56]. 
MSCs could promote endogenous regeneration by providing a niche to enhance 
proliferation and differentiation of tissue-specific stem/progenitor cells. Munoz et al. 
(2005) reported that in the experiments in which human MSCs were injected directly 
into the hippocampus of immune-deficient rats, MSCs engrafted briefly in hippocampus 
and enhanced proliferation of the endogenous neural stem cells found in the 
hippocampus. In addition, the cells increased migration of neural stem cells and their 
differentiation into neural cells [47]. 
Numerous investigators have studied the immune modulatory effects of MSCs on 
both innate and adaptive immune responses. The cells could suppress proliferation, 
maturation, and pro-inflammatory functions of different types of immune cells such as 
monocytes, dendritic cells, T-cells, B-cells, and neutrophils. Parallel with suppressing 
pro-inflammatory responses, MSCs have been demonstrated to increase the generation 
of anti-inflammatory immune cells, that include regulatory T-cells as well as anti-
inflammatory phenotypes of macrophages [2]. One of the first preclinical experiments 
focusing on immune modulatory potential of MSCs was done by Bartholomew and 
colleagues (2002). They observed that injection of allogeneic MSCs prolonged skin-graft 
survival in primates [57]. Other investigators also reported i.v. infusion of MSCs 
significantly reduced demyelination of neurons, loss of function, and infiltration of pro-
inflammatory cells in the experimental autoimmune encephalitis (EAE) model for 
multiple sclerosis [58,59]. For the first time, immune modulatory effects of tMSCs were 
reported in clinical trials to improve bone marrow transplants with MSCs: administration 
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of allogeneic MSCs improved the manifestations of graft-versus-host disease (GVHD) in 
a few patients [60]. Despite all the reports about immunosuppressive roles of the cells, 
underlying mechanisms of their actions are partially known. Some observations suggest 
that cell-to-cell contact with immune cells is required for these effects. In addition, 
immune modulatory effects of MSCs may be explained by the soluble factors secreted 
by these cells, including inducible nitric oxide synthase (iNOS), indoleamine 
dioxygenase (IDO), monocyte chemoattractant protein (MCP-1, also known as 
chemokine (C–C motif) ligand 2 (CCL2)), and prostaglandin E2 (PGE2) [2]. 
Recent reports demonstrated that MSCs also modulate inflammation [56]. Even 
though inflammatory responses have essential roles in eliminating foreign agents, 
removing damaged cells, and promoting tissue repair, a growing body of evidence 
suggests accentuation, prolongation, or expansion of inflammation worsen tissue 
deterioration and loss of function. Excessive or non-resolving inflammation has also 
been known to contribute to the pathogenesis of diseases such as obesity, diabetes, 
myocardial infarction, stroke, Parkinsonism, and Alzheimer’s disease [61]. 
Inflammatory stimuli have been shown to activate MSCs to secrete arrays of soluble 
factors and affect different aspects of inflammatory responses; therefore, MSCs could 
modulate excessive inflammation without significant tissue engraftment as was 
suggested in the crosstalk paradigm [56]. Searching for the mechanisms in which MSCs 
reduced inflammation and protected cardiac function in the murine model of myocardial 
infarction, Dr. Lee et al. (2009) analyzed transcriptomal alteration of trapped MSCs in 
the lungs of experimental mice 10 hours after i.v. infusion. Using both human- and 
mouse-specific microarrays for RNA isolated from the lungs, they observed wide ranges 
of human and mouse transcripts upregulated or downregulated post MSCs 
administration. Among several candidate genes, upregulation of human TNFAIP6 gene, 
which encodes tumor necrosis factor (TNF) stimulating gene 6 protein (TSG-6), was 
confirmed by real-time RT-PCR assays [51]. TSG-6 is a 35 kDa secreted protein. 
Previous studies demonstrated that TSG-6 expression has been observed in different 
pathological contexts that are associated with inflammation. The strong anti-
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inflammatory activity of this protein has been studied in both wild-type and transgenic 
mice [62,63]. Experiments with recombinant human TSG-6 and siRNA demonstrated 
that secreted TSG-6 largely accounted for the anti-inflammatory and cardio-protective 
effects of MSCs mouse model of myocardial infarction. Paralleled with in vivo 
observation, treated MSCs with recombinant TNFα in culture were activated to express 
TSG-6 mRNA [51]. Secretion of TSG-6 by MSCs was also demonstrated in a model of 
chemical-induced cornea injury in rats. Intraperitoneal (i.p.) and i.v administration of 
human MSCs were shown to significantly reduce the amount of myeloperoxidase (MPO, 
enzyme released in injured tissue mainly by activated neutrophils) and pro-inflammatory 
cytokines [64]. In addition, MSC therapy decreased development of opacity in the 
cornea. Similar to the mouse model of myocardial infarction, knockdown of the TSG-6 
gene negated the beneficial effects of MSCs. Also, administration of recombinant human 
TSG-6 could reproduce the beneficial outcomes of MSC therapy. A quantitative assay 
for human mRNA for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
demonstrated insignificant numbers of MSCs detectable in the corneas of rats 1 day and 
3 days after i.v. or i.p. administration [64]. In a mouse model of zymosan-induced 
peritonitis, Choi et al. (2011) demonstrated that secreted TSG-6 from MSCs and its 
recombinant protein suppressed the initial production of pro-inflammatory cytokines: 
TSG-6 decreased activation of nuclear factor (NF)-κB in the resident macrophages and 
therefore fewer neutrophils were recruited to the site of injury, which led to lesser tissue 
damage [65]. In addition to TSG-6, stimulation of MSCs with different pro-
inflammatory cytokines activated the cells to secrete variety of anti-inflammatory 
mediators such as transforming growth factor beta (TGF-β), PGE2, IL-10, IL-1 receptor 
antagonist (IL-1ra), soluble receptor 1 for TNF (sTNFR1), and stanniocalcin-1 (STC-1) 
indicating that MSCs can suppress inflammation through a variety of mechanisms [56].   
Another therapeutic potential of MSCs was shown to be cytoprotection [56]. 
Hypoxic culture conditions activated MSCs to increase production of several 
angiogenesis and anti-apoptosis factors such as IL-6, vascular endothelial growth factor 
(VEGF), and MCP-1/CCL2 [66]. In addition, Block and colleagues (2009) observed that 
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apoptosis was reduced in the previously UV irradiated fibroblasts co-cultured with 
MSCs in a transwell system [67]. Comparative microarray analysis of cultured MSCs in 
the presence or absence of UV irradiated fibroblasts demonstrated that apoptotic cells 
activated MSCs to secrete STC-1. The use of anti-STC-1 blocking antibody attenuated 
the anti-apoptotic effect of MSCs [67].   
Overall, the current data indicate that although bone marrow-derived MSCs were 
first proposed to differentiate into injured tissue, their therapeutic effects mostly result 
from their broad range of responses to different microenvironments. MSCs release anti-
inflammatory cytokines as well as anti-apoptotic and trophic molecules to protect the 
damaged tissues and promote tissue repair. These cells produce significant beneficial 
effects when administered to experimental animals. Also, they have demonstrated few if 
any adverse effects; therefore, MSCs are likely to continue to be the most widely used 
cells for new clinical trials in patients. 
 
I.2 Stanniocalcin-1: the Multitasking Secretory Protein  
STC-1 is the mammalian homologue of STC, which was originally identified as a 
calcium/phosphate-regulating hormone in bony fish. Formerly called hypocalcin or 
teleocalcin, STC is a homodimeric glycoprotein secreted by small endocrine glands in 
fish called corpuscles of Stannius. STC-1 in mammals is produced by a variety of tissues 
and has been proposed to regulate a variety of physiological and pathological functions 
in a paracrine/intracrine fashion [68-70].  
 
I.2.1. Stanniocalcin in fish 
In 1839, Stannius described corpuscles of Stannius as cream-colored bodies 
located ventrally on the surface of the fish kidney. He thought corpuscles of Stannius 
were fish adrenal glands; therefore, initially emphasis was on identifying their 
steroidogenic capacity, but to no avail [68,71]. More than a century after the discovery 
of corpuscles of Stannius, Fontaine (1964) found that the surgical removal of these 
glands led to a transparent hypercalcemia in European eel. Interestingly, the animals 
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were unperturbed by elevated serum calcium levels in the 5-6 mM range and eventually 
restored their normocalcemia. The mode of recovery is still not completely understood. 
Stanniectomized eels held in acalcemic water did not develop hypercalcemia, which 
suggested the significant role of exogenous calcium in the calcium hemostasis in fish 
[71,72]. Fenwick and his colleagues identified that the gills of eels lacking corpuscles 
had at least 10 fold higher rates of calcium transport [72]. Furthermore, the injection of 
corpuscles of Stannius glandular extracts were found to reduce gill calcium transport, 
both in vivo and in vitro in isolate perfused gills. This finding hinted that an active 
principle(s) or inhibitory factor(s) in the corpuscles of Stannius extracts might regulate 
the rate of gill calcium transport [73,74]. Other investigators showed hypocalcemic 
activity in the corpuscles of Stannius of different types of fish as well [71,75,76]. 
I.2.1.1. Structure of fish stanniocalcin protein 
Two major active principles were later isolated from corpuscles of Stannius: a 
substance with pressor activity [77] and a glycosylated protein [78,79]. While the 
characteristic of pressor substance was still being investigated [80], the studies for the 
hypocalcemic principle of corpuscles of Stannius of fish, STC, indicated that the protein 
had a unique amino acid sequence as compared to other known mammalian hormones 
[79,81-83]. In most fish species, STC is a homodimeric molecule. On the basis of cDNA 
sequencing in salmonids, the precursor of proSTC monomer is 256 residues in length. A 
hydrophobic segment is cleaved off during translation to yield a 64 kDa proSTC, which 
is then processed over a period of minutes into the mature monomer of 223 residues. 
Glycosylation at an Asn-linked consensus site adds ~5 kDa to the protein core. Two-
dimensional gel electrophoresis indicated the presence of several isoforms of proSTC 
and mature STC molecules that may reflect different stages of maturation of the 
(pro)hormone [71,84]. During translation, 10 of the 11 cysteines form intrachain 
disulfide linkages, leaving the last (Cys169) to form the interchain dimer [83]. In arawana 
and several other osteoglossiform species the 11th cysteine is replaced by arginine 
(Cys169-Arg169), making these the only known vertebrates in which STC exists in 
monomeric form [85]; however, the effect of this mutation on STC bioactivity has not 
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yet been addressed. Synthetic N-terminal fragments (1–20) of fish STC monomers were 
shown to have inhibitory effects on gill calcium transport, albeit at much reduced 
potency. Also, the loss of the first four N-terminal amino acids significantly reduced the 
effect of STC [86,87], suggesting that the bioactive portion of this hormone resides in 
the N-terminus. Verbost et al. observed that the midfragment of STC conceivably 
contained a major antigenic site of the hormone [87]. In salmon, the C-terminus of STC 
has been shown to undergo truncation [88], but the effect of this process on hormone 
potency has not yet been identified [71].  
I.2.1.2. Tissue expression of fish stanniocalcin 
STC was originally believed to be made only by corpuscles of Stannius cells in 
fish. However, the gene is now known to be expressed in most tissues at much lower 
levels and could account for the ability of fish to re-establish normal calcium balance 
after stanniectomy. Gonads and kidneys have the highest levels of extra-corpuscular 
gene expression. The ovaries have been shown to produce a more heavily glycosylated 
form of STC hormone [89,90]. The function of this STC variant remains to be seen. 
Despite the tissue pattern of gene expression, the immunoassay of sera from fish 
maintained in waters of wide-ranging calcium concentrations (0.02-10 mM Ca2+) 
indicated that STC was always present in the blood, although not always in its bioactive 
form. Fish serum contained at least four smaller immunoreactive forms of STC in 
addition to the pro and mature hormone. It would appear that fish serum contains factors 
capable of modifying hormone activity, such as proteolytic enzymes cleaving STC at 
one or more sites in the protein core [91]. A rise in serum calcium levels is known to be 
the primary stimulus for promoting STC release from the corpuscles of Stannius glands 
[91]. The sensitivity of the cells to calcium is mediated by membrane-associated calcium 
sensing receptors (CaSR) [92,93]. This mechanism ensures that as serum calcium levels 
rise, STC is released to slow the rate of calcium entry via the gills. Calcium also 
stimulates STC translation [94], stabilizes pre-existing transcript [95], and increases 
transcript levels as much as 6-fold in cultured corpuscles of Stannius cells [71]. Recent 
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studies suggested that Na+ and Cl- ions might regulate STC release from corpuscles of 
Stannius as well [96]. 
I.2.1.3. Function of fish stanniocalcin 
Calcium transport is an important and evolutionarily conserved process. In fish, 
STC regulates serum calcium homeostasis via the inhibition of branchial/ intestinal 
calcium uptake [91]. In addition, STC promotes phosphate reabsorption by the kidneys 
[97], which might be intended to chelate excess calcium in the serum and deposit into 
bone and scales. Although the exact mechanism by which STC inhibits gill calcium 
transport is not known; this biological action of STC has been widely used as a standard 
bioassay to test the hypocalcemic potency of corpuscles of Stannius extracts or the 
recombinant STC protein [79,91,98]. In studies on isolated flounder proximal tubules, 
Renfro and colleagues have shown that STC has dose-dependent stimulatory effects on 
G protein coupled signaling cascade activating the PKA pathway [97]; however, the 
structure of STC receptors in fish or mammals have not been identified. Chloride cells of 
the gills are responsible for regulated calcium transport and have been suggested to be 
sites of STC action [99]. Butler and colleagues have suggested that STC may redirect 
blood flow away from areas of the gill that are rich in chloride cells as a means of 
reducing calcium transport [100]. One other proposed mechanism could be the transfer 
of calcium back to water by yet-uncharacterized transporters. Alternatively, STC might 
promote calcium chelation within the cytosol of chloride cells or its uptake by a 
subcellular organelle such as mitochondria. Then the trapped cation could be released to 
the bloodstream in accordance with normal physiological demands. While studying 
fractionated gills, Flik (1990) ruled out low- and high-affinity Ca2+-ATPases as being 
regulated by STC. He suggested that STC might close calcium channels in the apical 
membranes of chloride cells, thereby reducing their calcium permeability [94]. Recently, 
STC has been found to reduce calcium uptake via the inhibition of epithelial Calcium 
channel mRNA expression [101], which could explain the calcium regulatory 
mechanism of STC in fish.  
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I.2.2. Stanniocalcin-1 in mammals 
Originally, STC was assumed to be unique to fish. No corpuscles of Stannius 
glands or any comparable structures have been identified in mammals. In addition, 
calcium/phosphate homeostasis in mammals has been replaced by parathyroid hormone, 
calcitonin, and 1,25-dihydroxyvitamin D [70]. The first suggestion that there might be a 
mammalian STC was based on immunoreaction of STC with human serum and kidneys 
[102]. Mammalian homologue of STC was thereafter isolated independently in two 
laboratories. Chang et al. (1995) identified a cDNA that was downregulated following 
immortalization of simian virus 40 (SV40) early region-transformed human fibroblasts. 
The sequence of the new cDNA was found to share ~60% identity and ~73% similarity 
with amino acid sequences of various fish STCs. Due to its high degree of homology to 
fish STC, this novel mammalian protein was also named STC [103]. Olsen and 
colleagues (1996) identified the same gene during random sequencing of an early-stage 
human fetal lung cDNA library [98]. Two years after the identification of the 
mammalian STC, a second human and mouse STC gene was identified by several 
groups searching expressed sequence tag (EST) databases for sequences related to 
human STC [104-107]; Consequently, fish and mammalian STC was renamed STC-1 
and STC-related protein was named STC-2. In 2005, fish STC-2 was also cloned from 
various fish species [108].  
I.2.2.1. Structure of mammalian stanniocalcin-1 protein 
The human STC-1 cDNA encodes a protein of 247 amino acids. The level of 
sequence similarity to salmon STC-1 is 92% over the first 204 amino acids; however, the 
last 43 residues at the C-terminus are completely different. The human STC-2 cDNA 
encodes a protein of 302 amino acids that has 34% identity to human STC-1. The 
relatedness of STC-2 to STC-1 is greatest at the N-terminus [109]. In addition, an 
unusual feature of STC-2 is the presence of 15 histidine residues, four of which are 
present as a cluster at the C-terminus of the protein. Moore et al. (1999) utilized a nickel-
chelating column to purify STC-2 [107], which suggest that these histidines may bind to 
transition metals [109]. Together, these findings suggest that STC-1 is more closely 
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related to fish STC-1 than to human STC-2 [107,109]. Nevertheless, mammalian STC-1 
and STC-2 are secreted phosphoglycoproteins and the site of a glycosylation consensus 
sequence [Asn-X- Thr(Ser)] is conserved between the two proteins. They both contain 
PKC/PKA consensus sequences. Another conserved feature of STC proteins is the 
presence and location of cysteine residues, which cause mammalian STC proteins to 
form homodimers in their native state. Also, mammalian stanniocalcin genes have four 
exons and display conserved exon-intron boundaries implying that STC-1 and STC-2 
may be derived from a common ancestral gene [71,110]. 
I.2.2.2. Tissue distribution of mammalian stanniocalcin-1 
Mammalian STC-1 mRNA is expressed in various tissues. The highest level of 
expression is found in the kidney, ovary, prostate, and thyroid [98,103]. It was 
previously assumed that STC-1 protein does not circulate in the blood of mammals 
[111]; however, recent reports suggest that mammalian STC-1 is blood borne and likely 
attached to a soluble protein [110,112]. Interestingly, the distributions of STC-1 mRNA 
and protein do not always parallel. In the kidney for example, STC-1 protein was 
detected along the entire nephron, albeit the mRNA expression that was restricted to the 
cortical and medullary collecting ducts [113,114]. Recently, STC-1 binding protein 
(receptor) has been detected in cells of the kidney, liver, breast, and ovaries using 
stanniocalcin-alkaline phosphatase fusion protein, which can explain the wide 
distributions of STC-1 protein [115-118]. STC-1 binding sites were found mainly on 
mitochondria and to a lesser extent to the external cell membranes and nucleus. Analysis 
of membrane fractions also revealed that STC-1 was associated with the inner matrix of 
mitochondria [115]. Structural information on STC-1 receptor, its role in ligand 
sequestration, or its possible involvement in subsequent hormone action have not yet 
been described. Nevertheless, these findings suggest that STC-1 functions in a 
paracrine/intracrine manner [69].  
Like STC-1, mammalian STC-2 is ubiquitously expressed. The primary sites of 
STC-2 expression are the pancreas, spleen, kidney and skeletal muscle [105,106]. Its 
localization in pancreatic alpha cells suggests involvement of STC-2 in glucose and 
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energy metabolism [107]. Consistent with this, deletion of STC-2 produces overweight 
mice [119]. Abnormalities in the expression of STC-2 have also been associated with 
various malignancies [109]. There is no available information on the serum level of 
STC-2 in mammals and it is believed that STC-2 may function as a paracrine/autocrine 
factor as well.  
I.2.2.3.  Regulation of stanniocalcin-1 expression  
To better understand the possible roles for STC-1 in mammals, regulation of its 
mRNA expression was examine by several investigators. Chang et al. (1995) found that 
the steady-state STC-1 mRNA level in immortalized human fibroblasts was elevated 
almost 10-fold by a 2.5-fold increase in the calcium concentration of the culture medium 
[103]; therefore, mammalian STC-1 mRNA levels are affected by extracellular calcium 
concentration. The active metabolite of vitamin D3 was also shown to increase STC-1 
mRNA levels in rat kidneys more than 3-fold, which could be due to vitamin D3-induced 
hypercalcemia. Interestingly, regulation of STC-1 expression was tissue-specific; 
vitamin D3 metabolite didn’t increase the STC-1 mRNA levels in the ovaries [120]. 
Sheikh-Hamad et al. (2000) also observed 8-fold increase in STC-1 mRNA caused by 
growth in hypertonic medium of canine renal cell line. This induction of STC-1 mRNA, 
however, was dependent upon an extracellular calcium concentration greater than 0.1 
mM, confirming a role for extracellular calcium in STC-1 regulation [121]. 
Likewise, STC-1 mRNA was significantly increased during endothelial 
differentiation of human umbilical vein cells observed by Kahn et al. (2000)  [122] and 
during capillary morphogenesis in 3-dimensional collagen matrices [123]. STC-1 was 
later identified as a downstream target of VEGF/Wnt2 signaling pathway [122,124,125] 
indicating STC-1 involvement in angiogenesis. Utilizing differential display analysis of 
mRNA from human umbilical vein endothelial cells treated with 
lysophosphatidylcholine, a component of oxidized lipoproteins with proatherogenic 
properties, Sato et al. (1998) observed transitory expression of STC-1 mRNA [126]. 
Expression of STC-1 was also found to be induced in human glioblastoma cells and in 
the brain and heart of mice in response to hypoxia [127-129]. A study of temporal gene 
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expression in serum-stimulated human fibroblasts, often used to investigate wound 
repair, demonstrated that STC-1 mRNA was upregulated two hours after stimulation 
[130]. The expression of STC-1 has further been associated with tumor suppression. 
BRCA1 is a tumor-suppressor gene, which its mutations can lead to breast and ovarian 
cancer. In an in vitro study designed to identify transcriptional targets of BRCA1, STC-1 
was shown to be induced by 2-4 fold increases in the expression of BRCA1 [131]. 
Together these results indicate that expression of mammalian STC-1 is controlled in a 
tissue-specific manner by a variety of stimuli and suggest STC-1 may play distinct roles 
in angiogenesis, in wound repair, in the response to hypoxia, and in the pathogenesis of 
carcinogenesis and atherosclerosis.  
Studies on human tumor samples revealed that STC-1 was differentially 
expressed in a number of cancers compared with the relevant normal tissues; some 
examples include breast carcinomas, ovarian cancers, colorectal cancers, hepatocellular 
carcinoma, and non-small cell lung cancers [70,109]. Since, STC-1 mRNA has been 
considered to be a molecular marker for various types and stages of cancers. 
Furthermore, some clinical studies on different cancer types have correlated the high 
expression levels of STC-1 to poor prognostic outcome. For example, the survival rate of 
leukemia patients with high STC-1 mRNA levels in their peripheral blood was lower 
[132]. However, a larger sample size with identified developmental stage is necessary to 
support this diagnostic relationship.  
I.2.2.4. Stanniocalcin-1 function in mammals 
As a result of STC-1 being highly expressed in ovaries and due to the fact it is 
detectable in serum during pregnancy and lactation, its roles in development were 
studied by generating two transgenic STC-1-overexpressing mice. Circulating STC-1 
protein was detectable in both transgenic mouse lines [133,134]. The muscle-specific 
STC-1 transgenic mice displayed the dwarf phenotype. These mice had increased 
cartilage matrix and decreased bone length with smaller muscles. There were 
abnormalities in skulls and long bones of the transgenic mice proposing that STC-1 has a 
role in both intramembranous and endochondral bone formation. Blood pressure and 
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serum phosphate levels were normal, but serum calcium levels were elevated; the latter 
finding was attributed to stimulated osteoclast activity. Notably, transgenic mice were 
hyperphagic compared with wild-type littermates and consumed more oxygen. Muscle-
specific STC-1 transgenic mice also had leaner fat pads and faster clearance of glucose. 
These mice were noted to have mitochondrial swelling [133]that can arise from 
increased respiration and/or enhanced mitochondrial ion transport. In the second STC-1 
transgenic mouse line(s), strong preferential expression of the transgene was detected 
mostly in the liver, heart, brain, endothelial cells, and macrophages [134,135]. 
Overexpression of STC-1 resulted in permanent and severe dwarfism. In addition, the 
reproductive ability of female transgenic mice was compromised. Serum calcium levels 
were normal, while serum phosphate levels were slightly higher. Overall, these 
observations suggested that STC-1 is involved in different stages of development. 
Subsequently, the STC-1 knockout mouse line was generated to identify the 
normal function of this protein. However, no anatomical or histological abnormalities 
were detected in any tissues [136]. Because physiological parameters and animal 
phenotypes are regulated by complex signaling crosstalk and the function of many gene 
products, the observed changes in the knockout and transgenic mice may not accurately 
reflect the functions of STC-1 gene [70]. 
Due to the similarity of STC-1 to its fish counterpart, it seemed likely that 
mammalian STC-1 was involved in regulation of calcium and phosphate concentration at 
a tissue or cellular level. In addition, calcium concentration was shown already to 
influence expression of STC-1. Interestingly, recombinant human STC-1 was shown to 
inhibit branchial calcium transport in fish [98] and intestinal calcium absorption in swine 
and rat [137]. Also, recombinant STC-1 stimulated the renal and intestinal reabsorption 
of phosphate [137,138]. Analysis of phosphate uptake in vesicles isolated from rat renal 
tubular brush-border membrane has suggested that the sodium-phosphate transporter 
may be a target of STC-1 activity [138]. Furthermore, STC-1 was found to play a role in 
bone mineralization via a functional relationship with the type III sodium-phosphate 
transporter in osteoblasts [139]. Sheikh-Hamad et al. (2003) reported a regulatory role of 
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STC-1 on intracellular calcium. STC-1 was shown to inhibit transmembrane calcium 
currents via L-type channels in rat cardiomyocytes [140]. Collectively, these studies 
imply that mammalian STC-1 can locally regulate calcium and phosphate levels [70]. 
The local action of mammalian STC-1 was further studied on neural cells. Zhang 
et al. (2000) observed that treatment of Paju cells with recombinant STC-1 in vitro 
stimulated their uptake of phosphate. Phosphate is known to buffer intracellular free 
calcium and protect neural cells from apoptosis, since elevation of intracellular free 
calcium, during brain injuries such as ischemia, is neurotoxic and can cause apoptosis in 
neural cells. In addition, the cytoprotective role of this protein was studied in STC-1-
overexpressing Paju cells in vitro. The cell viability was significantly increased in these 
cells compared to control cells in response to hypoxia stress as well as toxic levels of 
intracellular free calcium. Interestingly, transient upregulation of STC-1 was seen in 
human and rat brain neurons at the edges of infarcted areas suggesting therapeutic 
potential of STC-1 in neural cells challenged by ischemia and calcium-mediated injuries 
[141]. 
Observations from transgenic mice suggested that STC-1 might regulate 
metabolism of energy via its localization at the inner membrane of mitochondria and its 
concentration-dependent stimulatory effect on electron transfer [115,133]. In order to 
better address the effects of STC-1 on mitochondria, Ellard and colleagues (2007) 
isolated intact mitochondria from rat muscle and liver and exposed them to increasing 
concentrations of recombinant human STC-1.  They observed that respiration rate was 
significantly increased in isolated mitochondria; while ATP synthesis was reduced 
thereby suggesting STC-1 was involved in uncoupling of oxidative phosphorylation 
[142]. Subsequently, Wang et al. (2009) reported that recombinant human STC-1 
upregulated the expression of mitochondrial uncoupling protein-2 (UCP2) in cultured 
macrophages. This finding was concurrent with diminishing mitochondrial membrane 
potential and superoxide generation in both untreated and lipopolysaccharide (LPS)-
stimulated macrophages. Despite of the reduction in cellular ATP level, STC-1 appeared 
to enhance cell viability [143]. UCPs are mitochondrial anion carriers that localize at the 
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inner membrane of mitochondria and facilitate proton leak from the mitochondrial inter-
membrane space to the matrix, which diminishes the proton gradient and uncouples 
oxidative phosphorylation. UCPs are activated by reactive oxygen species (ROS) and 
their metabolites during oxidative stress. Excessive ROS and their products could 
damage cells and induce apoptosis. UCPs create a negative feedback loop to reduce 
production of ROS in mitochondria and protect cells from oxidative damage. UCP2 is 
widely expressed in tissues, including the spleen, thymus, macrophages, hypothalamus, 
pancreatic β-cells, and stomach. UCP3 is another members of the mitochondrial anion 
carrier family, which induces proton leak in skeletal muscle, brown adipose tissue, and 
to a lesser extent in the heart [110,144]. Notably, STC-1 was shown later to upregulate 
expression of UCP3 and reduce superoxide generation in angiotensin II-treated 
cardiomyocytes in vitro. Recombinant STC-1 failed to suppress superoxide generation in 
isolated cardiomyocytes from UCP3-/- mice, suggesting that the effects of STC-1 on 
ROS generation in cardiomyocytes are UCP3-dependent [145]. As mentioned before, 
MSCs were shown to enhance cell survival through upregulation and secretion of STC-1 
[67]. Administration of recombinant STC-1 produced similar effect on hypoxic lung 
cancer cells and was reported to be partly UCP2 dependent [146]. These observations 
revealed that STC-1 acts as a key regulator of ROS generation and protects cells from 
oxidative stress in a tissue-specific manner [70,110]. 
Kanellis et al. (2004) reported that recombinant STC-1 diminished the 
intracellular calcium signals in macrophages and attenuated the responses of cultured 
murine macrophages and human monocytes to chemokines. In addition, they observed 
that STC-1 is strongly induced in the kidney following obstructive injury and in 
macrophages, suggesting STC-1 may serve as endogenous anti-inflammatory agent and 
attenuate the infiltration of inflammatory cells to the site of tissue injury [147].  Later, 
recombinant STC-1 was shown to attenuate the migration of cultured macrophages and 
T cells across a quiescent or cytokine-treated endothelial cells in vitro [148]. As 
mentioned, STC-1 decreased ROS generation in LPS-stimulated macrophages [143]. 
Production of mitochondrial ROS is known to potentiate NF-κB activity in immune 
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cells; therefore, emphasizing an anti-inflammatory role for STC-1 [110,149]. Anti-
inflammatory actions of STC-1 were further studied in the mouse model of anti-
glomerular basement membrane glomerulonephritis. After anti-glomerular basement 
membrane treatment, STC-1 transgenic mice exhibited diminished infiltration of 
inflammatory macrophages in the glomeruli, decreased interstitial fibrosis, reduced 
expression of CXC motif ligand 2 (CXCL2) and TGF-β in the kidney, and preserved 
kidney function when compared with wild-type mice [135]. Anti-inflammatory and 
therapeutic potentials of STC-1 were confirmed in various disease models such as 
ischemia/reperfusion kidney injuries, retinal degeneration, and sepsis, in which STC-1 
reduced generation of ROS and infiltration of immune cells to the injured tissues [150-
152]. Whether these effects are related to antioxidant property of STC-1, regulation of 
intracellular calcium concentration, or other mechanisms remains to be determined.  
Collectively, these observations revealed that through the evolutionary process 
from fish to mammals, STC-1 has maintained functional relevance to calcium/phosphate 
homeostasis, while acquiring additional paracrine/intracrine roles and functions in the 
various organs in which it is expressed. The mechanisms for pleiotropic actions of the 
protein have not been entirely defined; however, most studies emphasized the 
therapeutic applications of STC-1 in numerous diseases.  
 
I.3. Monocytes and Macrophages in Tissue Homeostasis and Disease Pathogenesis 
Monocytes and macrophages are heterogeneous mononuclear phagocytes with 
crucial but distinct roles in tissue homeostasis and immunity. Monocytes play a 
significant role during inflammation and pathogen challenge, while tissue-resident 
macrophages have important functions in development, tissue homeostasis and the 
resolution of inflammation. Moreover, monocytes and macrophages contribute to 
pathogenesis of a broad spectrum of diseases making these cells attractive therapeutic 
targets.  Therefore, novel clinical strategies are essential that aim to manipulate these 
cells. For example, depleting monocytes/macrophages when their effects are detrimental 
or enhancing their mobilization when their activities are advantageous [153].  
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I.3.1. Monocyte and macrophage development  
Monocytes and macrophages as well as dendritic cells (DCs) are part of the 
mononuclear phagocyte system (MPS) originally described as a main phagocytic 
population of bone marrow-derived myeloid cells that could circulate in the blood and 
populate tissues in the steady state and during inflammation [154-156]. Monocytes are a 
conserved population of leukocytes. Mature cells have heterogeneous morphology, 
which are defined by their location, phenotype, characteristic gene, and microRNA 
(miRNA) expression signatures. These cells constitute ∼5–10% of peripheral blood 
leukocytes in mice and humans. In addition, considerable numbers of monocytes are 
stored in the spleen and lungs that can be mobilized on demand [157]. Monocytes arise 
from their precursor cells in primary lymphoid organs, including the fetal liver and bone 
marrow, during both embryonic and adult hematopoiesis. In mice, monocytes are also 
produced from precursors in the spleen during inflammation [158]. Monocyte 
development and survival in mice have been suggested to be completely dependent on 
M-CSF, since mice suffering deficiency in this growth factor or its receptor CSF1R 
exhibit severe monocytopenia [153,156,159]. 
Macrophages are the most plastic cells of the hematopoietic system. These cells 
are found in all tissues. Tissue-resident macrophages are morphologically distinct from 
one another, have different transcriptional profiles, and diverse functional capabilities. 
Ebert and Florey (1939) first reported that monocytes emigrated from blood vessels and 
developed into macrophages in the tissues [155]. Several other investigators also 
observed that circulating monocytes differentiate into macrophages during inflammation. 
In addition, studying the fate of monocytes revealed that the cells have a short half-life 
of 20 hours in blood, which together led to the assumption that blood monocytes 
constitute the main precursor reservoirs for tissue-resident macrophages. However, the 
most recent data have demonstrated that monocytes do not significantly contribute to 
most tissue-resident macrophages in the steady state or during certain types of 
inflammation. Adult tissue-resident macrophages are found to originate prenatally from 
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the yolk sac- or fetal liver-derived precursors that seed the tissues before birth. These 
cells can maintain themselves in adults by self-renewal, including the macrophages in 
the central nervous system (CNS) called microglia. Nevertheless, monocytes can, and 
do, give rise to macrophages in certain settings as well as during inflammatory 
circumstances [153,156,160]; for instance, at the tissues with considerable exposure to 
microorganisms and their products such as intestine recruitment and differentiation of 
circulating monocytes have been observed to maintain macrophage pools. That perhaps 
is the result of low-grade chronic inflammation caused by the constant presence of 
commensal microorganisms [161]; therefore, resident macrophages are constituted from 
mixed lineage-committed precursors in healthy adult animals [160]. 
 
I.3.2. Monocyte and macrophage subsets in human and mouse  
Monocytes are divided into subsets on the basis of expression of chemokine 
receptors and the presence of specific surface molecules. Human monocytes were 
initially identified by their expression of large amounts of CD14 (which is a co-receptor 
for LPS). Currently, there are two main human monocyte subpopulations: CD14high 
(CD14hi) monocytes and CD14low monocytes. Differential expression of CD16 (also 
known as Fc receptor FcγRIII) allowed the first population of monocytes to be divided 
into two subsets of CD14hiCD16- and CD14hiCD16+ monocytes. CD14hiCD16- 
monocytes, referred to as classical monocytes, are the most abundant subset of 
circulating monocytes in humans. CD14low monocytes express CD16 as well, which are 
referred to as non-classical monocytes. Distinct expression of chemokine-receptors has 
been recognized between all these subsets [153,162,163]: for example, CD14hiCD16+ 
monocytes expressed CC-chemokine receptor 5 (CCR5), whereas CD14hiCD16- 
monocytes expressed CCR2. 
Murine monocyte subsets were first identified by differential expression of 
CCR2. CCR2 is also expressed in HSCs and is a subset of natural killer (NK) cells 
mediating migration of the leukocytes (monocytes) from bone marrow to the blood 
stream. CCR2+ subset shows higher migratory and infiltration capacity than CCR2- 
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subset of monocytes and was initially considered to be the inflammatory monocyte. 
Currently, mouse monocyte subsets are characterized by differential expression of an 
inflammatory monocyte marker Ly6C (Gr1). The cells are grouped as CD11b+Ly6Chi 
and CD11b+Ly6Clow. Moreover, mouse CD11b+Ly6Chi monocytes, which are similar to 
human CD14hi monocytes, express CCR2 on their surface and have been shown to 
represent approximately 2–5% of circulating white blood cells in an uninfected mouse. 
Whereas, CD11b+Ly6Clow mouse monocytes express low levels of CCR2 and are 
considered being equivalent to human CD14lowCD16+. The latest subset of mouse and 
human monocytes express high levels of CX3-chemokine receptor 1 (CX3CR1) that is 
important in leukocyte adhesion to the endothelial cells [153,163,164]. 
Macrophages are categorized into subpopulations based on their anatomical 
location and functional phenotypes. Specialized tissue-resident macrophages include 
alveolar macrophages (lung), Langerhans cells (skin), osteoclasts (bone), and Kupffer 
cells (liver) [162,165]. Macrophages isolated from the lamina propria have a unique 
phenotype, which is characterized by high phagocytic and bactericidal activity but weak 
production of pro-inflammatory cytokines. Interestingly, this phenotype can be induced 
in peripheral blood-derived macrophages by products of intestinal stromal cells 
indicating the influence of microenvironment on macrophage polarization and function 
[161,162]. In addition to macrophage heterogeneity in different organs, different 
subpopulations of macrophages have been observed in a single organ, such as spleen, 
skin, and CNS [162,165,166].  
There is a great overlap in surface marker expression between the different 
macrophage subsets; thus, a useful characterization approach has been based on the 
profile of gene expression in response to cytokine or microbial stimulation. Several 
macrophage subsets with distinct functions have been described, including classically 
activated macrophages (M1) and alternatively activated macrophages (M2) consist of 
regulatory macrophages and wound-healing macrophages as well as tumor-associated 
macrophages (TAMs). Although there are obvious differences among the M2, regulatory 
macrophages, and TAMs, they all exhibit immune suppressive activity. Numerous 
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studies have documented macrophages switching from one functional phenotype to 
another in response to diverse stimuli indicating that macrophages represent a spectrum 
of activated phenotypes rather than discrete stable subpopulations [165,167]. 
 
I.3.3. Monocyte and macrophage function in tissue homeostasis and disease 
I.3.3.1. Monocyte/macrophage tissue homeostasis in the steady state 
In regards to the fate of circulating monocytes under normal circumstances, there 
is some evidence to suggest that Ly6Chi monocytes differentiate into Ly6Clow cells in the 
circulation. Mouse Ly6Clow monocytes, and their human CD14lowCD16+ equivalent, 
have been demonstrated to patrol the integrity of the luminal side of endothelium of 
small vessels and migrate to non-inflamed organs [163,164,168]. Moreover, Ly6Clow 
cells have recently been shown to coordinate intraluminal stress responses. They induce 
the recruitment of neutrophils, which trigger focal necrosis of endothelial cells and, then, 
Ly6Clow monocytes clear the cellular debris [153,168]. 
The function of Ly6Chi monocytes in the steady state remains poorly defined. 
Highlighting their potential physiological importance, however, it was recently reported 
that Ly6Chi monocytes are mobilized from the bone marrow in diurnal rhythmic waves, 
suggesting a role for these monocytes in supporting the innate immune system against 
predicted environmental challenges. Since chronic inflammatory diseases, such as 
myocardial infarction, asthma, and rheumatoid arthritis, exhibit diurnal clustering in 
humans, circadian release of inflammatory Ly6Chi monocytes might also contribute to 
the pathogenesis of those diseases [153,169]. 
Experimental depletion of tissue-resident macrophages has been shown that, 
under certain conditions, circulating monocytes can reconstitute the populations of 
Langerhans cells, microglial cells, and CX3CR1+ mononuclear phagocytes in the 
intestinal lamina propria. Monocyte-to-macrophage differentiation following the 
experimental depletion of resident macrophages does not necessarily reflect the natural 
processes that occur during the development tissues homeostasis as mentioned before 
[153,162]. Nevertheless, the ability of monocytes to reconstitute distinct tissue 
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macrophage and DC populations suggests an important physiological role for monocytes 
following tissue trauma or infection. 
Metchnikoff initially described macrophages in the late 19th century as 
phagocytic cells. Currently, macrophages are known for their vital roles in tissue 
development and homeostasis in addition to their involvement in immune responses 
[164,165]. Phagocytosis, particularly of apoptotic cells, is a critical function for 
macrophages in the remodeling of tissues during development, for example the 
resolution of the inter-digit areas during limb formation [159]. The importance of 
macrophages in development has been studied in Csf1op/op mice, which lack many 
macrophage populations, and revealed a cluster of developmental abnormalities. Most 
notable among these was the development of osteopetrosis (stone bone). In these mice 
bone formation was unchanged but the tissue remodeling and expression of growth 
factors were deficient, which is caused by the loss of bone-reabsorbing osteoclasts 
[159,170]. Macrophages also have been shown to regulate angiogenesis during 
development through a number of mechanisms [160,171].  
Macrophages are found in mammalian metabolic organs, including liver, 
pancreas and adipose tissue, which function together with parenchymal cells to maintain 
metabolic homeostasis. By regulating this interaction, mammals are able to make 
marked adaptations to changes in their environment and in nutrient availability such as 
during infection. Tissue-resident macrophages are also involved in maintaining tissue 
homeostasis by removing dead or dying cells and toxic materials. For example, alveolar 
macrophages facilitate the removal of allergens from the lung, while Kupffer cells 
participate in the clearance of pathogens and toxins from the circulation [160]. 
Macrophages are also involved in recycling erythrocytes and neutrophils in the spleen 
and liver to maintain the steady state of hematopoiesis [160,172]. Additionally, 
macrophages ingest the extruded nuclei of maturing erythroblasts, which is crucial for 
host survival [173]. All together, these processes occur independently of immune-cell 
signaling, and the removal of apoptotic or dying cells seems to result in little or no 
production of immune responses by unstimulated macrophages.  
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I.3.3.2. Monocyte/macrophage responses to danger signals 
Tissue-resident macrophages and other mononuclear phagocytes are part of first 
line of the host defense. They are located throughout the body and constantly survey 
their surroundings for signs of tissue damage or invading organisms. Sensing danger 
signals is crucial for activation of macrophages. Activated macrophages then largely 
polarized to the inflammatory M1 phenotype to phagocytize pathogens and terminally 
injured cells. They also secrete pro-inflammatory mediators to recruit monocytes and 
neutrophils from their reservoir such as peripheral blood, bone marrow, and spleen to 
migrate to the site of injury or infection. Moreover, these mediators stimulate bone 
marrow to generate large pools of monocytes and neutrophils from HSCs beyond the 
normal requirements of a healthy organism. The production of monocytes and 
neutrophils is dependent on cytokines such as G-CSF and chemokines including MCP-
1/CCL2 and CCL5. Then, a mixture of mature and immature monocytic and 
granulocytic cells exits the bone marrow. Monocytes enter the damaged organs and 
differentiate into a spectrum of mononuclear phagocytes in response to 
microenvironmental signals, and contribute to the establishment of local inflammation, 
host defense, and tissue and wound repair. Antigen-presenting mononuclear phagocytes 
also migrate to the nearest lymph nodes and activate lymphocytes to initiate adaptive 
immunity [61,165,167].  
Mouse Ly6Chi monocytes, and their human CD14hi equivalent, express CCR2 
and can be rapidly mobilized to the injured tissues. During early stages of 
immunity/inflammation, these monocytes are more likely to mature to inflammatory 
mononuclear phagocytes. They have a high phagocytic capability to remove infectious 
agents, apoptotic neutrophils, and cell debris. In addition, these cells secrete pro-
inflammatory mediators such as TNFα, nitric oxide (in murine) and IL-1, which 
participate in the activation of various antimicrobial mechanisms, including oxidative 
processes. ROS and reactive nitrogen intermediates produced by inflammatory 
monocytes and monocyte-derived cells are highly toxic for microorganisms; however, 
they are also highly damaging to neighboring tissues and lead to aberrant inflammation. 
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Therefore, pro-inflammatory and antimicrobial responses must be controlled to prevent 
extensive collateral tissue damage to the host [164,165,167].  
Recruited Ly6Clow monocytes mainly differentiate into M2 phenotype, which 
exhibit potent anti-inflammatory activity. Some of the inflammatory 
monocytes/macrophages might also convert into anti-inflammatory M2 phenotype upon 
exposure to microenvironment. M2 macrophages phagocytose dead cells, debris, and 
other factors that would promote tissue-damaging responses. In addition, expression of 
immunoregulatory factors such as IL-10 by these cells have been shown to decrease the 
magnitude and duration of inflammatory responses and promote wound healing. M2 
macrophages produce growth factors, including TGF-β1 and platelet-derived growth 
factor (PDGF), to stimulate epithelial cells and fibroblasts and regulate wound healing. 
They also secrete matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs 
(TIMPs) that control extracellular matrix turnover. In order to inhibit excessive fibrosis, 
M2 macrophages produce factors that induce apoptosis in activated fibroblasts 
[165,167]; therefore, macrophages and their factors are integrated into all stages of the 
fibrotic process. 
Recently, tissue-resident macrophages were demonstrated to undergo massive 
proliferation in TH2-mediated inflammation. IL-4 produced by TH2 cells was shown to 
be the key factor stimulating macrophage proliferation. Although, the signaling 
mechanism regulated by IL-4 to push macrophages into the cell cycle remains unclear, 
these observations propose that proliferation at site is an alternative mechanism of 
inflammation, which allows macrophages to accumulate in sufficient numbers and 
perform critical functions such as parasite elimination and wound repair in the absence 
of immune cell recruitment [174]. 
Migration, differentiation, and function of monocytes and macrophages are 
crucial for host defense and tissue homeostasis; however, the uncontrolled 
immune/inflammatory responses also have the potential to do harm. For example, 
excessive activation of inflammatory monocytes/macrophages can cause damage to host 
tissues, predispose surrounding tissue to neoplastic transformation and influence glucose 
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metabolism by promoting insulin resistance. On the other hand, disregulation of M2 
macrophages can trigger unwanted fibrosis, which lead to loss of function and 
exacerbate allergic responses. In addition, parasitic, bacterial, and viral pathogens can 
induce the development of anti-inflammatory M2 phenotype to enhance their survival in 
the host. Therefore, maintaining a proper balance between the functions of these 
different phenotypes in vital for the survival of the host [153,165,167]. Better 
understanding of the mechanisms involved in regulation of monocyte-to-macrophage 
differentiation, their polarization and functions would improve therapeutic strategies for 
pathological conditions such as wound healing, autoimmunity, and cancer. 
I.3.3.3. Sensing danger signals via Toll-like receptors and their co-receptor CD14  
The first step for innate immunity and inflammatory responses is to sense the 
danger signals from injured tissues or invading organisms. Tissue-resident macrophages 
are among the first group of cells to detect danger signals through a group of germline-
encoded receptor proteins. These receptors recognize specific patterns that are shared by 
groups of pathogens, but not the host, and are termed pattern recognition receptors 
(PRRs). PRRs are expressed in immune and non-immune cells and detect pathogen-
associated molecular patterns (PAMPs) such as LPS found on the cell surface of Gram-
negative bacteria, or double-stranded RNA present in viruses. It is now evident that 
PRRs also recognize non-infectious material that can cause tissue damage and 
endogenous molecules that are released during cellular injury. These endogenous 
molecules have been named damage-associated molecular patterns (DAMPs) and have 
similar functions as PAMPs in terms of their ability to activate pro-inflammatory 
pathways [61,165,175]. Endogenous DAMPs are normally sequestered intracellularly 
and, therefore, hidden from recognition by immune system. Necrosis, resulting from 
trauma or stress, generates cellular debris that are loaded with these DAMPs, including 
heat-shock proteins, nuclear proteins (e.g. high-mobility group box 1 protein (HMGB1)), 
histones, DNA and other nucleotides, and components of the extracellular matrix [167]. 
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Toll-like receptors (TLRs) are the best characterized class of PRRs and are 
important regulators of innate immune responses. These receptors are type I 
transmembrane glycoproteins, which their cytosolic domain involved in the recruitment 
of different combinations of signaling adaptor molecules such as myeloid differentiation 
primary-response protein 88 (MyD88). Through the adaptor proteins, TLRs can activate 
downstream kinases that stimulate transcription factors such as NF-κB and activator 
protein 1 (AP-1), thus, inducing the production of pro-inflammatory cytokines and type I 
interferons (IFNs). Markedly, the activation of NF-κB pathways has been shown to 
upregulate the expression of anti-inflammatory molecules (e.g. IL-10) [61,176]. Thirteen 
mammalian TLRs have been identified (TLR1-10 in humans, TLR1-9 and TLR11-13 in 
mice), which are associated with the recognition of one or more PAMPs and DAMPs 
[175,176].  
Different types of membrane-bound or soluble co-receptor proteins assist TLRs 
to catch and concentrate scattered ligands and present them to TLRs. In addition, they 
help to define the specificity or increase the affinity of homo- or hetero-TLR dimers for 
a ligand. Co-receptors also deliver TLRs and their ligands to an optimal subcellular 
compartment to activate signals. Interestingly, TLR-co-receptors have been shown to 
transduce TLR-independent signals, which lead to distinct inflammatory responses 
[176,177]. Glycoprotein CD14 is a co-receptor well known for its role in recognition of 
endotoxin ligand, LPS. This protein is either anchored to the outer leaflet of the plasma 
membrane or released in the blood as a soluble mediator. CD14 is predominantly 
expressed by myeloid lineage cells such as monocytes and macrophages; however, 
several studies have shown that it can also be present in non-immune cells, including 
epithelia, smooth muscle cells, and fibroblasts. The co-receptor presents LPS to the 
TLR4 complex and enhances the following TLR4-mediated responses to the endotoxin 
[176,177]. CD14 knockout mice were shown to be less sensitive to LPS and more 
resistant to endotoxic shock, indicating the important role for CD14 [178]. Interestingly, 
this co-receptor is capable of recognizing several types of non-endotoxin ligands and, 
thus, contributing to the inflammatory responses mediated by different TLRs, including 
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TLR2 and TLR3. Lipopeptides, peptidoglycan, HMGB1 as well as dsRNA are examples 
of the identified ligands for different binding sites of CD14 [176,177,179].  
Overall, TLRs and their co-receptors have been recognized as key mediators 
initiating inflammatory responses by immune and non-immune cells and have been 
linked to the pathogenesis of many conditions, including autoimmune diseases, cancers, 
and cardiovascular diseases [175,176]. Therefore, understanding the detailed 
mechanisms regulating the expression and function of TLRs and their co-receptor could 
facilitate developing therapeutic strategies to modulate inflammatory responses by 
activated immune cells such as monocytes/macrophages.   
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CHAPTER II  
PROJECT HYPOTHESES AND SPECIFIC AIMS  
 
II.1. Enhanced Therapeutic Potential of Preactivated Mesenchymal Stromal Cells 
and Their Secretory Factor Stanniocalcin-1 in Models for Acute Injuries and 
Inflammation 
MSCs are a heterogeneous subset of stromal stem cells. These cells are relatively 
easy to isolated from bone marrow of human donors and patients. A large number of the 
cells can also be isolate from adipose and synovial tissues as well as umbilical cord 
blood. In addition, MSCs can expand rapidly for 30 or more population doublings in 
culture are highly clonogenic, but not tumorigenic. They can differentiate into cells of 
the mesodermal lineage, such as adipocytes, osteoblasts and chondrocytes.  Together, 
these attractive features of MSCs offer broad implications in clinic; therefore, 
therapeutic potential of the cells were tested in numerous animal models and in clinical 
trials. Initially, it was assumed that MSCs repaired tissues by engrafting and 
differentiating to replace injured cells. Instead, the cells were shown to enhance tissue 
repair and limit tissue destruction by paracrine secretions, cell-to-cell contacts, and 
transfer of exosomes or mitochondria [180-183].  
The potential paracrine effects of MSCs have been suggested by the observations 
that the cells in culture secrete a large number of cytokines and growth factors; however, 
these cells are activated by danger signals from injured cells to express high levels of 
additional genes [1,54,55]. Several studies have shown that stimulation of MSCs with 
different pro-inflammatory cytokines activated the cells to secrete variety of anti-
inflammatory mediators [56]. One of the anti-inflammatory molecules secreted by MSCs 
is the TSG-6 molecule. Expression of this protein was shown to upregulate in i.v. 
infused MSCs in a mouse model of myocardial infarction. MSCs were aggregated in 
pulmonary microvasculature and activated to secrete TSG-6. During the activation of 
MSCs, however, a large number of the cells underwent apoptosis and necrosis. 
Administration of recombinant human TSG-6 protein produced was shown to reduce 
  33 
inflammation and protect cardiac function after induction of myocardial injury, similar 
to the MSCs treatment [51]. TSG-6 has also been reported to play a major role in anti-
inflammatory and immune modulatory effects of MSCs in several animal models, such 
as zymosan-induced peritonitis, cornea injury, and lung injury [64,65,184]. Interestingly, 
MSCs do not produce TSG-6 in standard 2 dimensional (2D) cultures. Incubation of 
MSCs with recombinant TNF-α in the cultures activates the cells over time to secrete 
TSG-6 [51,65]. Another stress responsive molecule secreted by MSCs is STC-1. 
Expression of STC-1 was upregulated in MSCs by signals from dying cells and is 
involved in anti-apoptosis properties of MSCs [67]. Also, STC-1 was secreted in 
response to caspase activation and inflammatory cytokines in vitro [185,186]. Anti-
inflammatory and anti-apoptotic properties of STC-1 have been reported recently in a 
number of disease models, including anti-glomerular basement membrane 
glomerulonephritis, ischemia/reperfusion kidney injuries, retinal degeneration, and 
sepsis [135,150-152]. In addition to pretreatment of MSCs with exogenous factors, 
modifications of the culture conditions, such as hypoxia and serum deprivation, were 
demonstrated to promote their self-activation and expression of wide ranges of factors 
for cell protection [187].  These observations suggest that stimulation of MSCs in culture 
before administration might enhance their potential for therapeutic applications by 
eliminating the lag period for upregulation of beneficial factors in the host. This 
approach would be especially important in modulation of acute inflammatory phase. 
Recently, there has been increasing interest in culturing cells in non-adherent 3D 
conditions to overcome many limitations of using MSCs and other stem cells for clinical 
applications. The traditional 2D culture and differentiation methods widely used in 
current MSCs research yield single cells with limited cell-to-cell contact and result in 
low differentiation efficacy for the cells [188]. One of the advantages of culturing cells 
in 3D is that it more closely reproduces their natural environment. In 3D cell cultures, 
cells can form aggregates, in which nearly all of cell surface area being exposed to other 
cells or extracellular matrix. These cells extensively interact with each other and with 
their environment via soluble and membrane bound factors. In addition, extracellular 
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matrix is made of complexes of proteins, which are important mediators of numerous 
biological processes. Therefore, growing cells in 3D cultures generates important 
differences in cellular characteristics and behavior such as differentiation, proliferation, 
viability, drug metabolism, gene expression, morphology, and responses to stimuli [189].  
Different 3D culture methods have been used to generate MSC spheroids in vitro, 
that include culture in spinner flask or gyratory rotation system, microcarrier beads, 
microchannel culture system, and hanging drops [189]. A number of investigators have 
demonstrated that assembly into spheroids enhanced many properties of MSCs. For 
instance, culturing MSCs in low adherent plates or on micropatterned glass substrates 
could significantly improve their differentiation potency [188,190,191]. In addition, 
medium conditioned by MSCs cultured in hanging drops was shown to stimulate cell 
survival, proliferation, and in vitro migration and invasion of endothelial cells to a much 
higher extent than CM of 2D-cultured MSCs [192]. 3D cultures also altered expression 
of cell surface molecules responsible for the regulation of MSC homing [193]. Notably, 
MSCs aggregates were shown to attach to the underlying tissue and improve cardiac 
function more efficiently than dissociated cells, when injected into the peri-infarcted 
zone following myocardial infarction in rats [194]. Overall, 3D culture systems were 
indicated as a practical method to preactivate MSCs in culture in order to enhance their 
therapeutic potential in clinic. 
In order to benefit from MSCs in medicine and extend their therapeutic 
applications, alternative approaches have been also considered by investigators. Several 
soluble factors released by activated MSCs have been able to reproduce many of the 
anti-inflammatory responses in the cells suggesting these factors could replace MSC 
therapy. Protein therapy has many attractions; especially for the patients whom cell 
administration is not an option. Also, therapeutic application of recombinant proteins is 
preferred in acute injuries such as myocardial infarction or stroke since immediate care 
is crucial for short- and long-term prognosis after the injury. Several factors secreted by 
MSCs are not promising candidates for medical therapy. Some of them were shown to 
have short half-lives or limited applications and some could generate adverse effects 
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when administered systemically [56]. However, there appears to be adequate reasons for 
testing certain proteins such as STC-1 for therapeutic uses. Administration of STC-1 was 
reported to diminish intracellular calcium signal in macrophages and reduce their 
responses to chemokines. Also, it could suppress ROS production in LPS-stimulated 
macrophages. Moreover, anti-inflammatory and anti-apoptotic effects of STC-1 have 
been demonstrated in several models [150-152]. Thus, STC-1 is considered as a 
potential alternative in several pathological conditions such as acute ischemia-induced 
injuries. 
Myocardial infarction is a leading cause of morbidity and mortality worldwide. 
Despite advances in therapy to reduce mortality in acute phase, the incidence of chronic 
heart failure in patients surviving form myocardial damage has increased [195,196]. 
Following myocardial infarction, infarct area and the non-infarcted myocardium of the 
left ventricle undergo extreme structural alterations, referred to as ventricular 
remodeling. Excessive ventricular remodeling manifests clinically as increased chamber 
dilation and myocardial hypertrophy, which leads to impaired cardiac function and 
subsequently heart failure. The size of the necrotic area and the quality of cardiac repair 
are important factors in development of post-infarct heart failure [196,197]. Cardiac 
repair is supported by a well-orchestrated inflammatory response that serves to clear the 
wound from dead cells and debris, while activates reparative pathways necessary for scar 
formation. Timely repression and containment of inflammatory signals are essential to 
ensure optimal formation of a supportive scar in the infarcted area and to prevent 
development of adverse ventricular remodeling. For instance, excessive early 
inflammation may augment matrix degradation, which causes cardiac rupture. It can also 
activate apoptosis in cardiomyocytes of border zones and expand the scar size. In 
addition, ineffective containment of inflammatory responses may lead to extension of 
inflammation to the non-infarcted myocardium enhancing fibrosis and worsening 
diastolic function [195-197]. Therefore, strategies to regulate post-infarct inflammatory 
pathways will improve the prognosis of patients with myocardial infarction.   
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Myocardial tissue injury induces the release of endogenous danger signals, 
including inflammatory cytokines and chemokines, ROS, and intracellular DAMPs (e.g. 
HMGB1, heat shock proteins, membrane fractions). These signals trigger intense 
inflammatory responses by activating the innate immune system. Timely suppression 
and resolution of post-infarct inflammation requires the coordinated actions of several 
different cell types such as monocytes and macrophages. Several observations from 
experimental animals and patients have indicated that distinct subsets of monocytes are 
recruited at different stages of post myocardial infarction and can differentiate into a 
spectrum of macrophage populations. The first wave of monocytes facilitates the 
removal of dead cardiomyocytes and the later phase promotes the resolution of 
inflammation and tissue repair [163,165]. The detailed mechanisms that regulate 
activation, deactivation, and differentiation of monocytes/macrophages in myocardial 
injury are not defined yet; however, developing multifunctional strategies that regulate 
these processes could help improving the prognosis of patients with acute myocardial 
injuries.  
In this work we proposed two hypotheses: “aggregation of MSCs in 3D cultures 
provides an effective procedure to pre-activate the cells, and thereby, enhance their 
therapeutic effects through reduction in the lag period for secretion of anti-inflammatory 
factors in vivo” and “STC-1, a pleotropic factor secreted by MSCs, modulates 
differentiation and function of monocytes/macrophages and protects heart from ischemic 
cardiac damage in part by suppressing inflammation after myocardial infarction.”  
 
II.2. Specific Aims 
To test these hypotheses, we performed experiments based on two aims.  
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II.2.1.  To study the enhanced therapeutic potentials of spheroid MSCs 
II.2.1.1. Establish the optimal conditions to improve anti-inflammatory properties of 
cultured MSCs in the hanging drop system 
In order to identify a new approach for self-activation of MSCs in vitro, the 
hanging drop method was used to culture the cells in a 3D system. This method is 
simple, inexpensive, and does not require specific equipment. Spheroids produced in the 
hanging drop system are uniform in size and shape. It is also possible to control the 
culture conditions in the hanging drop system. Therefore, this approach could facilitate 
studying the unique properties of 3D-cultured MSCs. There is a wide range of factors 
that can be modified in the hanging drop system and can influence the characteristics 
and the functions of MSCs. Since the main goal of this study was to enhance production 
of anti-inflammatory factors by MSCs, the optimal conditions for hanging drop cultures 
that maximizes expression of TSG-6 were defined. Previous studies on the properties of 
MSCs in standard 2D culture system revealed that morphology of the cells alters in the 
confluent cultures and following several passages. In addition, certain environmental 
modifications could cause remarkable changes in the characteristics of MSCs [19,56]; 
therefore, some of the properties of MSCs dissociated from spheroids were tested, 
including survival rate as well as their colony formation and differentiation potentials. 
The findings of this study would help establish the optimal 3D culture conditions, which 
yield MSCs with enhanced anti-inflammatory potential. As a result, the therapeutic 
benefits of MSCs from donors with low rate of paracrine secretion in standard 2D 
culture, could be improved as well. 
II.2.1.2. Demonstrate anti-inflammatory effects of activated spheroid MSCs in vitro and 
in vivo 
Resident macrophages are stimulated at early stages of tissue injury to secrete a 
large number of pro-inflammatory cytokines and chemokines, activate immune system, 
destroy pathogens, and remove the death cells. The balance between pro- and anti-
inflammatory actions of these cells is important in the outcome of tissue repair [160]. In 
the current work, the effects of spheroids and their derived MSCs were investigated on 
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LPS-stimulated macrophages in vitro. In addition, the enhanced anti-inflammatory 
potential of these cells was compared to the standard 2D cultured cells in a mouse model 
of zymosan-induced peritonitis. Zymosan binds to TLR2 on resident macrophages. This 
complex stimulates NF-κB signaling and secretion of TNF-α and other pro-inflammatory 
cytokines and chemokines. These observations would help determine future therapeutic 
applications of 3D cultured MSCs. 
 
II.2.2. Study the therapeutic benefits of recombinant STC-1 protein 
II.2.2.1. Examine anti-inflammatory effects of recombinant STC-1 on monocyte and 
macrophages in vitro 
In response to danger signals, circulating monocytes activate and migrate to the 
site of injury, where they differentiate into a spectrum of macrophage subsets. 
Regulation of these processes is crucial for the outcomes of different conditions such as 
myocardial injuries and heart failure. Previously, STC-1 was reported to diminish 
intracellular calcium signals in monocytes/macrophages in response to different 
chemokines and reduce their migratory potential in vitro and in vivo [147]. In the current 
work, the effects of STC-1 on monocyte-to-macrophage differentiation by a number of 
stimuli were studied. In addition, the effects of STC-1 treatment on inflammatory 
responses of LPS-stimulated monocytes/macrophages were determined. These results 
can help better understand the mechanisms for anti-inflammatory actions of STC-1. 
II.2.2.2. Demonstrate therapeutic potentials of recombinant STC-1 in preclinical model 
of myocardial infarction 
Suppression of inflammatory pathways has been reported to improve outcome 
after myocardial infarction. Pro- and anti-inflammatory roles of monocytes/macrophages 
are crucial for the progression and resolution of myocardial infarction. To determine the 
effects of STC-1 on cardiac inflammation and function a mouse model of myocardial 
infarction was used. The recombinant protein was intravenously administered to the 
experimental animals and the amounts of inflammatory mediators in the cardiac tissue 
were measured. In addition, cardiac function and infarct size of STC-1 treated mice was 
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compare with controls. These observations, for the first time, revealed anti-inflammatory 
and cardiac protective roles of STC-1 in ischemia-induced myocardial injury. 
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CHAPTER III  
MANUSCRIPT 1: 
AGGREGATION OF HUMAN MESENCHYMAL STROMAL CELLS INTO 3D 
SPHEROIDS ENHANCES THEIR ANTI-INFLAMMATORY PROPERTIES 
 
Previous reports suggested that culture as 3D aggregates or as spheroids can 
increase the therapeutic potential of the adult stem/progenitor cells referred to as 
mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs). Here we 
used a hanging drop protocol to prepare human MSCs as spheroids that maximally 
expressed TSG-6, the anti-inflammatory protein that was expressed at high levels by 
MSCs trapped in the lung after i.v. infusion and that largely explained the beneficial 
effects of MSCs in mice with myocardial infarcts. The properties of spheroid MSCs 
were found to depend critically on the culture conditions. Under optimal conditions for 
expression of TSG-6, the MSCs also expressed high levels of STC-1, a protein with both 
anti-inflammatory and anti-apoptotic properties. In addition, they expressed high levels 
of three anticancer proteins: IL-24, TNFα-related apoptosis inducing ligand, and CD82. 
The spheroid MSCs were more effective than MSCs from adherent monolayer cultures 
in suppressing inflammatory responses in a co-culture system with LPS-activated 
macrophages and in a mouse model for peritonitis. In addition, the spheroid MSCs were 
about one-fourth the volume of MSCs from adherent cultures. Apparently as a result, 
larger numbers of the cells trafficked through the lung after i.v. infusion and were 
recovered in spleen, liver, kidney, and heart. The data suggest that spheroid MSCs may 
be more effective than MSCs from adherent cultures in therapies for diseases 
characterized by sterile tissue injury and unresolved inflammation and for some cancers 
that are sensitive to anti-inflammatory agents. Bartosh et al., PNAS (2010) [198]. 
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III.1. Introduction 
There has been considerable interest in the therapeutic potentials of the cells 
from bone marrow referred to initially as colony forming units-fibroblastic, then as 
marrow stromal cells, subsequently as mesenchymal stem cells, and most recently as 
multipotent MSCs [10,16,21,181,199,200]. The cells are relatively easy to isolate from 
human donors or patients, expand rapidly for 30 or more population doublings in culture, 
and differentiate into several cellular phenotypes in vitro and in vivo. These and related 
properties prompted testing the therapeutic potential of the cells in animal models and in 
clinical trials for a large number of diseases (see www.clinicaltrials.gov). The initial 
assumption in exploring the therapeutic benefits of MSCs was that they might engraft 
and differentiate to replace injured cells. Engraftment and differentiation was observed 
in rapidly grown embryos, with extreme tissue injury, or after local administrations of 
large concentrations of the cells. Frequently, however, therapeutic benefits were 
observed without evidence of engraftment. Instead, the cells enhanced tissue repair or 
limited tissue destruction by paracrine secretions or cell-to-cell contacts that modulated 
inflammatory or immune reactions [2,10,180,181]. The potential paracrine effects of the 
cells were suggested by the observations that the cells in culture secrete a large number 
of cytokines [1,55]. Recent reports, however, have demonstrated that MSCs are activated 
by crosstalk with injured cells to express high levels of a large number of additional 
genes [48,51,54,55,67,201]. 
We previously observed [51] that i.v.-infused human MSCs (hMSCs) improved 
cardiac function and decreased scarring in a mouse model of myocardial infarction in 
part because the cells that were trapped in the lung as microemboli were activated to 
secrete the anti-inflammatory protein, TSG-6 [62]. The TSG-6 decreased the 
inflammatory reactions in the heart and thereby limited deterioration of the cardiac 
tissue. However, the hMSCs did not express TSG-6 until 12–24 h after they created 
microemboli in lungs and until about half the hMSCs had undergone destruction through 
apoptosis and necrosis. We also observed that standard cultures of hMSCs did not 
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express TSG-6 but were activated to express the protein if incubated for 24 h or longer 
with the inflammatory cytokine TNFα [51]. 
The observations suggested that appropriate manipulation of hMSCs in culture 
before in vivo administration might enhance their therapeutic benefits by eliminating the 
lag period for activation on the cells by signals from injured tissues. 
Recently there has been a series of publications on aggregation of MSCs either as 
a procedure for enhancing chrondrogenic differentiation of the cells [188,190,191] or to 
increase their therapeutic potential [193,194,202,203]. Because aggregated hMSCs were 
detected in the pulmonary microemboli observed after i.v. infusion of the cells [51,204], 
we tested the hypothesis that aggregation of hMSCs in culture may provide an effective 
procedure to preactivate the cells to express TSG-6, and thereby, enhance their anti-
inflammatory effects through a reduction in the lag period for expression of the gene in 
vivo. 
 
III.2. Materials and Methods 
 
III.2.1. hMSC cell culture  
Frozen vials containing about 1 million passage 1 hMSCs from bone marrow 
were obtained from the Center for the Preparation and Distribution of Adult Stem Cells 
(formerly http://www.som.tulane.edu/gene_therapy/distribute.shtml; currently 
http://medicine.tamhsc.edu/irm/msc-distribution.html). hMSCs were isolated from 1–4 
mL bone marrow aspirates of the iliac crest in normal adult donors. Nucleated cells, 
obtained by density gradient centrifugation (Ficoll-Paque; GE Healthcare), were 
resuspended in CCM: α-MEM (Gibco), 17% (v/v) FBS (Atlanta Biologicals), 100 
units/mL penicillin (Gibco), 100 µg/mL streptomycin (Gibco), and 2 mM L-glutamine 
(Gibco), seeded in 175 cm2 flasks (Nunc), and subsequently cultured at 37 °C in a 
humidified atmosphere with 5% (v/v) CO2. After 24 h, non-adherent cells were 
discarded. Adherent cells were incubated 4–11 d until approximately 70% confluent, 
harvested with 0.25% (w/v) trypsin and 1 mM EDTA (Gibco) for 5 min at 37 °C, and 
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replated at 50 cells/ cm2 in an intercommunicating system of culture flasks (Nunc). The 
cells were incubated for 7–12 d until approximately 70% confluent, harvested with 
trypsin/EDTA, and frozen as passage 1 cells in α-MEM containing 30% (v/v) FBS and 
5% (v/v) DMSO (Sigma). A frozen vial of passage 1 hMSCs (donor 1, 7064 L; donor 2, 
7068 L) was thawed, resuspended in CCM, and plated in a 152-cm2 culture dish 
(Corning). After 24 h, adherent cells were harvested using trypsin/EDTA, plated at 100 
cells/cm2, and expanded for 7 d before freezing. In this study, passage 1 or 2 frozen 
hMSCs were recovered, seeded at 100 cells/cm2 24 h later, and grown 7–8 d in CCM for 
various assays. 
 
III.2.2. Spheroid generation and dissociation 
To generate spheroids, hMSCs were plated as hanging drops on an inverted 
culture dish lid in 35 µL of CCM at 10,000–250,000 cells/drop. The lid was flipped and 
placed on a culture dish containing PBS (Gibco) to prevent evaporation. Hanging drop 
cultures were grown at 37 °C up to 4 d in a humidified atmosphere with 5% CO2. 
Spheroid generation in hanging drops was captured using a Photometrics Coolsnap HQ2 
camera mounted on a Nikon Eclipse Ti-E inverted microscope containing a temperature 
controlled environmental chamber. To collect spheroids, drops were harvested using a 
cell lifter, transferred to a 15 or 50 mL conical tube (Falcon), washed with PBS, and 
centrifuged at 453 × g for 5–10 min. To obtain spheroid derived cells, spheroids were 
incubated with trypsin/EDTA at 37 °C for 5–30 min (5 min for 10k, 10 min for 25k, 20 
min for 100k, and 30 min for 250k spheroids), while pipetting every 2–3 min. When no 
cell aggregates were visible, spheroid derived cells were collected by centrifugation at 
453 × g for 5–10 min to be used in described assays. 
 
III.2.3. Histology  
hMSC spheroids were collected with cell lifter (Corning), transferred into a 15-
mL conical tube, washed twice with PBS, and fixed with 2% (v/v) paraformaldehyde 
(PFA, USB Corporation) in PBS for 15 min at room temperature. Fixed spheroids were 
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washed twice with PBS, centrifuged at 500 × g for 10 min, and incubated at 4 °C 
overnight in 500 µL of 30% (w/v) sucrose solution (Sigma) in 0.1 M phosphate buffer 
(Sigma). After incubation, 800 µL of 30% (v/v) OCT (Sakura Finetek) in sucrose 
solution was added gently and the suspension was transferred into a histology mold. The 
mold was frozen in isopentane (Sigma) chilled by liquid nitrogen and stored at −80 °C. 
Cryosections (6 µm) were prepared with a Microm HM560 cryostat. For H&E staining, 
slides were first incubated at room temperature for 10–15 min, fixed in 4% PFA for 15 
min, and washed twice with deionized water. Rehydration was performed by incubating 
the samples in 100% ethanol (EMD Chemical) for 5 min, 95% ethanol for 2 min, 70% 
ethanol for 2 min, and deionized water twice for 5 min. The slides were stained with 
Mayer’s Hematoxylin (Electron Microscopy Science) for 15 min, rinsed with deionized 
water, incubated with Scott’s Tap Water Substitute (Ricca Chemical Company) for 2 
min, rinsed with deionized water, washed with warm tap water for 20 min, rinsed with 
deionized water, immersed in 95% ethanol for 1 min, and stained with Eosin Y 
(Mallinckrodt Baker) for 1 min. Slides were then dehydrated by immersion in 95% 
ethanol for 1 min, 95% ethanol for 5 min, 100% ethanol for 5 min, and xylene (EMD 
Chemical) for 5 min. Samples were air-dried and overlaid with coverslips for 
examination. Mounting media (VECTA Mount; Vector Laboratories) was used to 
preserve staining. Images were acquired on a Nikon Eclipse 80i upright microscope and 
processed using NiS Elements AR 3.0 software (Nikon). 
 
III.2.4. Real-time RT-PCR assays 
Total RNA was isolated from monolayer and spheroid hMSCs using RNeasy 
Mini Kit (Qiagen) with DNase (RNase-Free DNase Set; Qiagen) digestion step. RNA 
was converted into cDNA with High-Capacity cDNA RT Kit (Applied Biosystems). 
Real-time RT-PCR was performed in triplicate for 18 s, TSG-6 (TNFAIP6), STC1, LIF, 
IL-24, TNFα-related apoptosis inducing ligand (TRAIL), CXC chemokine receptor 4 
(CXCR4), and dickkopf 1 (DKK1) using TaqMan Gene Expression Assays (Applied Bio- 
systems). A total of 15–60 ng of cDNA was used for each 20-µL reaction. Thermal 
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cycling was performed with 7900HT System (Applied Biosystems) by incubating the 
reactions at 95 °C for 20 s followed by 40 cycles of 95 °C for 1 s and 60 °C for 20 s. 
Data were analyzed with Sequence Detection Software V2.3 (Applied Biosystems) and 
relative quantities (RQs) were calculated with comparative CT method using RQ 
Manager V1.2 (Applied Biosystems). If no amplification occurred, CT value of 35 was 
used in calculating the RQs. 
 
III.2.5. Viability assays  
Spheroid viability was measured by flow cytometry (FC500; Beckman Coulter) 
using Annexin V-FITC apoptosis detection kit (Sigma) per manufacturer’s instructions. 
Spheroids were collected and washed in PBS, followed by debris removal with a 40-µm 
cell strainer (Fisher). Spheroids were then transferred into a sterile centrifuge tube by 
inversion of the strainer and subsequently pelleted by centrifugation at 453 × g for 5 
min. The supernatant was aspirated and the spheroids dissociated in a six-well plate 
(Corning) at 37 °C using 2–3 mL trypsin/EDTA. After 5–30 min, the digest was 
neutralized with FBS, filtered through a 40 µm cell strainer to remove nondissociated 
particles, and centrifuged at 453 × g for 5–10 min to acquire a cell pellet. Approximately 
200,000 hMSCs derived from monolayer cultures or spheroids were incubated for 10 
min with 0.5 µg/mL annexin V-FITC and 2 µg/mL propidium iodide (PI) in 400 µL of 
1× binding buffer (10 mM Hepes, 0.14 M NaCl, 2.5 mM CaCl2). The cells were 
immediately placed on ice and analyzed. Cell fragments were removed by 
morphological gating. Cells negative for annexin V-FITC and PI were considered viable, 
annexin V-FITC positive and PI negative considered apoptotic, and annexin V-FITC 
positive and PI positive considered necrotic. 
 
III.2.6. Cell cycle analysis 
The cell cycle distribution in spheroids and monolayer cultures was determined 
by analyzing DNA content of permeabilized hMSCs labeled with PI (Sigma). hMSCs 
derived from monolayer or spheroid cultures were resuspended in 1 mL of ice cold PBS 
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containing 2% FBS followed by fixing with 3 mL cold absolute ethanol added dropwise 
while vortexing. The cells were incubated for 2–4 h in 4 mL of 75% ethanol to complete 
fixation, washed 3 times in PBS, then pelleted by centrifugation at 800 × g for 10 min. 
Cells were incubated with 7 U/mL RNase A (Qiagen) in 1 mL of PBS at room 
temperature. After 1 h, 50 µg/mL PI was added and the cells were incubated overnight at 
4 °C. DNA content was measured with a flow cytometer and data analyzed using 
MultiCycle software (Phoenix Flow Systems). 
 
III.2.7. Cell surface protein detection  
To analyze cell surface markers, hMSCs resuspended at 3.0 × 106 cells/mL in 
αMEM containing 2% FBS were labeled with the antibodies described (Table 1) for 40 
min on ice. The cells were washed 3 times with PBS and surface expression of proteins 
was determined with a flow cytometer. 
 
III.2.8. Spheroid derived cell sizing 
The size of hMSCs derived from adherent monolayers, or from dissociated 
spheroids suspended for 3 d in hanging drops at 10,000, 25,000, 100,000, and 250,000 
cells/drop, was determined by microscopy and flow cytometry. For microscopic 
analysis, the cells were transferred into chambers of a Neubauer improved disposable 
hemocytometer and images captured on a Nikon Eclipse Ti-S inverted microscope using 
a Ds-Fi1 camera (Nikon). Cell diameter of more than 50 cells per group was 
subsequently determined using NIS-Elements AR 3.0 software. For flow cytometric 
analysis of cell size, 2.0 × 105 hMSCs were resuspended in 400 µL αMEM containing 
2% FBS then incubated for 20 min with 100 nM of the live cell viability dye calcein AM 
(Molecular Probes) and 10 min with 2 µg/mL of the dead cell nuclear label 7AAD 
(Sigma). Cell sizes were estimated from the viable population (Calcein+/7AAD−) by 
comparing forward scatter (FS) properties of the cells and beads with a known diameter 
of 3, 7, 15, or 25 µm. Brackets were subsequently applied to the scatter plot at locations 
corresponding to the respective bead size. Gates established based on bead size FS were 
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used to group the cells into five populations (<3 µm, 3–7 µm, 7–15 µm, 15–25 µm, and 
>25 µm). 
 
III.2.9. Intravenous Infusion of hMSCs  
Male immunodeficient NOD/scid mice (NOD.CB17-Prkdcscid/J; The Jackson 
Laboratory), 7–8 week of age, housed on a 12 h light/dark cycle, were used to study the 
relative tissue distribution of the i.v. infused hMSCs. All animal procedures were 
performed with approval by the Animal Care and Use Committee of Texas A&M Health 
Science Center and in accordance with guidelines set forth by the National Institutes of 
Health. Mice were anesthetized by i.p. injection of a mixture of ketamine (91 mg/kg) and 
xylazine (9 mg/kg). Total of 106 monolayer or spheroid derived hMSCs suspended in 
150 µL of HBSS were infused slowly into a tail vein. Mice were anesthetized 15 min 
later with ketamine/xylazine (90 mg/kg and 9 mg/kg) and euthanized by exsanguination. 
Heart, lung, liver, spleen, and kidneys were isolated by dissection and stored at −80 °C 
for further analysis. 
 
III.2.10. Isolation of genomic DNA 
After thawing the tissues, 5 mL of 10 mM Tris HCl (pH 8.0) containing 20 µL 
proteinase K (10 mg/mL), 0.1 mM EDTA (pH 8.0), 0.5% (w/v) SDS, and 20 µg/mL 
RNase A was added to each sample. Samples were homogenized (PowerGen Model 125 
Homogenizer; Fisher Scientific) and incubated at 50 °C overnight on a shaker at 200 
rpm. DNA was extracted by mixing 0.5 mL of sample with 0.5 mL phenol/chloroform 
solution (pH 6.7) followed by centrifugation at 15,300 × g for 5 min in 2 mL phase lock 
gel tubes (Phase Lock Gel; Eppendorf/Brinkmann Instruments). To precipitate the DNA, 
1/2 volume of 2.5 M ammonium acetate, and the same volume of 100% ethanol was 
added, followed by overnight incubation at 4 °C. The precipitates were washed with ice 
cold 75% ethanol and resuspended into sterile water. 
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III.2.11. Real-time PCR assays for Alu sequences 
Real-time PCR assays for Alu sequences were performed in 50 µL containing 25 
µL Taqman Universal PCR Master Mix (Applied Biosystems), 900 nM each of the 
forward and reverse primers, 250 nM Taqman probe, and 200 ng of genomic DNA. 
Reactions were incubated at 50 °C for 2 min and at 95 °C for 10 min followed by 40 
cycles at 95 °C for 15 s and 60 °C for 1 min. Real-time PCR assays for human and 
mouse GAPDH genes were performed in 50 µL containing 25 µL SYBR Green Master 
Mix (Applied Biosystems), 200 nM each of the forward and reverse primers and 200 ng 
of genomic DNA. All real-time PCR assays were performed in duplicate or triplicate and 
average values are presented. The final value for total DNA in the sample was corrected 
by parallel real-time PCR assays with primers that amplified both the human and mouse 
GAPDH genes [51,204,205].  
 
III.2.12. Differentiation assays  
hMSCs derived from high density monolayer (5,000 cells/cm2) or hanging drop 
cultures (25,000 cells/drop), grown for 3 d, were seeded at low density (100 cells/cm2) 
on six-well dishes and were grown until 80–90% confluent. To induce adipogenesis, 
hMSCs were cultured in CCM supplemented with 500 nM dexamethasone (Sigma), 500 
nM isobutylmethylxanthine (Sigma), and 50 µM indomethacin (Sigma) for 14 d with 
medium changes every 3–4 d. To induce osteogenesis, hMSCs were cultured in CCM 
supplemented with 10 nM dexamethasone, 10 mM β-glycerolphosphate (Sigma), and 50 
µM Ascorbate-2-phosphate (Sigma) for 14 d with medium changes every 3–4 d. Parallel 
control cultures were maintained in CCM for 14 d with medium changes every 3–4 d. 
All wells were washed with PBS and fixed with 10% (v/v) neutral buffered formalin 
(Sigma) for 1 h. The adipogenic differentiation and control wells were washed with PBS 
and stained with 0.6% (w/v) Oil-Red-O (Sigma) solution in 60% isopropanol (Sigma) 
and 40% PBS for 20 min followed by washing with PBS. The osteogenic differentiation 
and control wells were washed with deionized water and stained with 40 mM Alizarin 
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Red S (Sigma) solution, pH 4.2, in water for 20 min followed by washing with water. 
Images were captured on a Nikon Eclipse Ti-S inverted microscope. 
 
III.2.13. Growth curves  
hMSCs derived from high density monolayer or hanging drop cultures were 
seeded at 100 cells/cm2 in 55-cm2 dishes (Corning) in quadruplicate and cultured for 7 d 
in CCM with medium changes every 3 d. After 7 d, cells were lifted with trypsin/EDTA, 
counted with hemocytometer, and replated. The process was repeated until cells reached 
senescence. 
 
III. 2.14. CFU-F assays 
hMSCs derived from high density monolayer or hanging drop cultures were 
seeded onto 55 cm2 dishes at 1.5 cells/cm2 in quadruplicate and cultured for 14 d in 
CCM. Medium was changed every 3–4 d. After 14 d, the plates were stained with 3% 
(w/v) crystal violet (Sigma) in 100% methanol (Sigma) for 5 min, washed with water, 
and air-dried. Plates were scanned on an EPSON Perfection 4490 Photo scanner and 
images were processed with Adobe Photoshop CS3. 
 
III.2.15. Microarrays  
hMSCs from two donors grown at low density for 7 d and at high density or in 
hanging drops for 3 d were harvested for total RNA. A total of 2 µg of RNA from each 
sample was applied for microarrays using Whole Transcript Sense Target Labeling 
Assay protocol (Affymetrix) according to manufacturer’s directions. Briefly, to 
minimize the background and thereby increasing the array detection sensitivity and 
specificity, rRNA reduction was performed for samples containing the Poly-A RNA 
controls (GeneChip Eukaryotic Poly-A RNA-Control Kit; Affymetrix) using the 
RiboMinus Transcriptome Isolation Kit (Invitrogen) with Magna-Sep Magnetic Particle 
Separator (Invitrogen) and Betaine (Sigma). RNA was concentrated with GeneChip IVT 
cRNA Cleanup Kit (Affymetrix) and used to prepare double stranded cDNA with 
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GeneChip WT cDNA Synthesis Kit (Affymetrix). Generated cDNA was used to produce 
cRNA with GeneChip WT cDNA Amplification Kit (Affymetrix), followed by cleanup 
with GeneChip Sample Cleanup Module (Affymetrix). The amount of cRNA was 
determined with spectrophotometer (SmartSpec Plus; Bio Rad) and 10 µg was used to 
generate cDNA with GeneChip WT cDNA Synthesis Kit (Affymetrix) followed by 
cRNA hydrolysis and cleanup of single-stranded cDNA with GeneChip Sample Cleanup 
Module. The amount of cDNA was determined with spectrophotometer and 5.5 µg was 
used for fragmentation with GeneChip WT Terminal Labeling Kit (Affymetrix). The 
fragmented cDNA was labeled using GeneChip WT Terminal Labeling Kit and 
hybridized (GeneChip Hybridization Oven 640; Affymetrix) on Human Exon 1.0 ST 
arrays (Affymetrix) using GeneChip Hybridization, Wash, and Stain Kit (Affymetrix). 
Arrays were washed and stained (GeneChip Fluidics Station 450; Affymetrix) using 
GeneChip Hybridization, Wash, and Stain Kit followed by scanning with GeneChip 
Scanner (Affymetrix). Data were normalized using robust multiarray (RMA) algorithm 
and gene level analysis was performed with Partek Genomics Suite 6.4 (Partek). Genes 
that were either up- or downregulated in spheroids at least twofold, compared with their 
monolayer counterparts, were used in hierarchical clustering. Significant Gene Ontology 
terms for up- and downregulated genes in spheroids were determined using the Partek 
software. The raw microarray data files will be available at the Gene Expression 
Omnibus website (http://www.ncbi.nlm.nih.gov/geo/). 
 
III.2.16. Analysis of hMSC-secreted soluble anti-inflammatory factors 
For TSG-6, STC-1, and LIF ELISAs, monolayer, spheroids, and spheroid derived 
hMSCs were seeded at equal cell density (200,000 cells/well or 8–25k spheroids/well) 
on tissue culture treated six-well dishes in 1.5 mL of CCM. In addition, hMSC spheroids 
were also suspended at 8 spheroids/well on non-adherent six-well dishes (Corning). 
After 24 h, images were acquired, conditioned medium was collected, and the cells were 
lyzed with 100 µL of modified RIPA buffer containing HALT protease/phosphatase 
inhibitors (Thermo Scientific). Conditioned medium was cleared of cellular material by 
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centrifugation at 500 × g for 10 min and stored at −80 °C. Total cellular protein was 
measured in whole cells lysates using the bicinchoninic acid (BCA)-dependent 
colorimetric detection method (Micro BCA Protein Assay Kit; Thermo Scientific). 
Human TSG-6 protein levels in conditioned medium were determined by ELISA as 
described [51] with some modifications. Briefly, wells of microplate strips (Costar) were 
coated overnight at 4 °C with 10 µg/mL TSG-6-specific monoclonal antibody (clone 
A38.1.20; Santa Cruz Biotechnology, Inc.) in 50 µL of 0.2 M bi- carbonate buffer (pH 
9.2). The plates were washed 3 times with 400 µL of 1× wash buffer (R&D Systems), 
blocked with 100 µL of 1× PBST (Cell Signaling) containing 0.5% BSA (Thermo), and 
incubated for 2 h with 50 µL of sample or recombinant human TSG-6 protein standards 
(R&D Systems) diluted in blocking buffer. Wells were subsequently washed and 
incubated with 0.5 µg/mL biotinylated antihuman TSG-6 (R&D Systems) in 50 µL of 1× 
PBST. After 2 h, the samples were incubated for 20 min with 50 µL of streptavidin-HRP 
(R&D Systems), then with 100 µL substrate solution (R&D Systems). The colorimetric 
reaction was terminated after 15 min with 2 N sulfuric acid (R&D Systems) and the 
optical density determined on a plate reader (FLUOstar Omega; BMG Labtech) at an 
absorbance of 450 nm with wavelength correction at 540 nm. Human STC-1 and LIF 
proteins were detected with commercially available ELISA kits (R&D Systems) 
following procedures described by the manufacturer. Two hundred µL of sample/well 
was used for the LIF ELISA and 100 µL for the STC-1 ELISA. The obtained values 
were normalized to total cellular protein content to account for loss of cell/spheroid 
transfer. 
 
III.2.17. Macrophage inflammatory assay 
J774A.1 mouse macrophages (ATCC) were cultured on 15-cm bacteriological 
dishes (Falcon) in high glucose DMEM (Invitrogen) supplemented with glutamax, 10% 
FBS, and penicillin/streptomycin. Subcultures were prepared by washing the cells from 
the dish every 2–3 d and replating at a ratio of 1:5 to 1:10 (v/v). For the inflammatory 
assay, macrophages (MФ) were seeded in the upper chamber of a 24-mm transwell 
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insert with 0.4-µm pores (Corning) at 400,000 cells/well followed by stimulation with 
0.1 µg/mL of LPS (Sigma). After 90 min, LPS was removed and the cultures replaced 
with fresh medium. Total of 200,000 monolayer hMSCs, 200,000 spheroid derived cells, 
or 8–25k spheroids were transferred to the plate beneath the transwell. After 5 h, 
medium conditioned by the macrophages was collected and clarified by centrifugation at 
500 × g for 10 min. A total of 50 µL of conditioned medium was used for mTNFα 
ELISA (Quantikine Kit; R&D Systems). Mouse macrophages were washed with PBS 
and harvested for RNA to quantify mTNFα expression levels by Real-time RT-PCR 
using Taqman Gene Expression Assay. 
 
III.2.18. Mouse model of peritonitis 
Male C57BL/6J mice (Jackson Laboratories), 6–8 week of age and housed on a 
12 h light/dark cycle, were used to study the anti-inflammatory action of hMSC 
spheroids on zymosan-induced peritonitis. All animal procedures were performed with 
approval by the Animal Care and Use Committee of Texas A&M Health Science Center 
and in accordance with guidelines set forth by the National Institutes of Health. The 
inflammatory compound Zymosan A (Sigma) was prepared at a concentration of 1 
mg/mL in PBS and autoclaved for 15 min to sterilize. To induce inflammation, 1 mL of 
the 0.1% (w/v) zymosan solution was administered i.p. Fifteen minutes later, either 1.5 × 
106 monolayer hMSCs, 1.5 × 106 spheroid derived cells, or 60–25k spheroids were 
administered i.p. through a 20-gauge needle or catheter in 150–200 µL of HBSS (Gibco). 
After 6 h, animals were killed by cervical dislocation and the exudates retrieved by 
peritoneal lavage using 1.5 mL sterile PBS, pH 7.4, containing a 1× concentration of 
Halt protease inhibitors (Thermo Scientific) and 5 mM EDTA (Thermo Scientific). The 
lavage volume was recorded and the cells removed by centrifugation at 500 × g for 10 
min. The protein-rich supernatants were then transferred to fresh microcentrifuge tubes, 
cleared of debris by centrifugation for 10 min at 10,000 × g, and stored at −80 °C. 
Amounts of peritoneal exudation were determined by subtracting the measured lavage 
volume of each sample from the averaged baseline volume. Twenty-four hours after cell 
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delivery, blood was collected from the right ventricle of anesthetized mice and 
transferred to Capiject clot activating tubes (Terumo Medical Corporation). The tubes 
were inverted 8–10 times and incubated at room temperature for 20–30 min to facilitate 
clot formation. The samples were centrifuged at 1500 × g for 10 min and the serum layer 
collected for measurements of plasmin activity. 
 
III.2.19. Measurements of inflammation in peritoneal exudates and blood serum 
Levels of inflammatory molecules TNFα, IL-1β, CXCL2, and PGE2 were 
determined from the peritoneal lavage using commercially available ELISA kits (R&D 
Systems). Fifty microliters of sample per well was used for the detection of TNFα, 25 µL 
for IL-1β (1:2 dilution), 6.7 µL for CXCL2 (1:7.5 dilution), and 3 µL for PGE2 (1:50 
dilution). Secreted MPO, a marker of neutrophil activity, was measured from the cell-
free lavage fluid with a mouse-specific MPO ELISA kit (Hycult Biotech) per 
manufacturer’s instructions. Total protein was evaluated with the Micro BCA protein 
detection kit (Thermo Scientific). Serum plasmin activity, a marker of inflammatory 
status, was ascertained by measuring time dependent cleavage of the chromogenic 
substrate Chromozym PL (Roche Applied Science) into 4-nitranline in 50 mM Tris-HCl 
(pH 7.4) and 0.9% NaCl. Absorbance at 405 nm was measured every 2 min for 30 min 
using the plate reader. The values were expressed as average change in absorbance/min. 
 
III.2.20. Data analysis 
Data are summarized as mean ± SD. Student’s t test was used to calculate the 
levels of significance (NS, P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001). 
 
III.3. Results 
 
III.3.1. Aggregation of hMSCs in hanging drops into spheroids 
To aggregate hMSCs, we used a hanging drop protocol. Time-lapse microscopy 
demonstrated that hMSCs cultured in hanging drops first formed a loose network and 
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then numerous small aggregates that gradually coalesced into a single central spheroid 
along the lower surface of the drop (Fig. III.1A). Once assembled, the spheroid did not 
increase in size but progressively compacted between 48 and 96 h. H&E staining of 
sections revealed the spheroids were solid throughout with small round cells evenly 
distributed and embedded in matrix (Fig. III.1B). The surface of the spheroid had a layer 
of epithelium-like cells that were more elongated and flatter. As expected, the sizes of 
the spheroids were dependent on the number of hMSCs suspended in the hanging drops 
(Fig. III.1E). hMSC spheroids of all sizes expressed and secreted very high levels of the 
anti-inflammatory molecule TSG-6 compared with either low or high density monolayer 
cultures, but spheroids of 25,000 cells (Sph 25k) showed the highest expression and 
secretion of TSG-6 (Fig. III.1C and D). Moreover, TSG-6 expression increased in a time 
dependent manner with spheroids of 25,000 hMSCs and was consistently much higher 
than in standard cultures of adherent hMSCs (Fig. III.1F). 
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Figure III. 1. The expression of TSG-6 was increased as hMSCs aggregated into spheroids in hanging 
drops. (A) Phase contrast microscopy showing the time course of the aggregation of 25,000 hMSCs into a 
spheroid in a hanging drop. (Scale bar, 500 µm.) (B) H&E staining of hMSC spheroid sections from 3-d 
hanging drop cultures. Surface (Top), and center (Middle and Bottom) of a spheroid. (Scale bar, 50 µm.) 
(C) Real-time RT-PCR measurements of TSG-6 expression in hMSCs shown as relative to Adh Low 
sample (n = 3). (D) ELISA measurements of TSG-6 secretion over 24 h from hMSCs grown for 3 d at 
high density or as hanging drops at different cell densities (n = 4). (E) Sizes of spheroids generated by 
hMSCs from two donors grown in hanging drops for 3 d. Sizes were measured from captured images of 
transferred spheroids (n = 7–13). (F) Real-time RT-PCR measurements of TSG-6 expression in hMSCs 
grown at high density or in hanging drops at 25,000 cells/drop for 1–4 d shown as relative to hMSCs 
grown at low density (n = 3). Values are mean ± SD. Abbreviations: RQ, relative quantity; Adh Low, 
hMSCs plated at 100 cells/cm2 for 7–8 d until about 70% confluent; Adh High, hMSCs harvested from 
same Adh Low cultures, plated at 5,000 cells/cm2 and incubated for 3 d; Sph 10k-250k, hMSCs harvested 
from same Adh Low cultures and incubated for 3 d in hanging drops at 10,000-250,000 cells/drop. Bartosh 
et al., PNAS (2010) [198]. 
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Figure III. 2. Viability of hMSCs in spheroids. (A and B) Viability of hMSCs as determined by flow 
cytometry measuring PI uptake and annexin V-FITC labeling. Spheroids were dissociated with 
trypsin/EDTA. Representative log fluorescent dot plots and summary of the data are shown. Values are 
mean ± SD (n = 3). Abbreviations: As in Fig. 1 with 1 d to 4 d indicating days of incubation. Bartosh et al. 
PNAS(2010) [198]. 
 
 
 
III.3.2. Viability of hMSCs in spheroids  
Because hMSCs in spheroids may have less access to nutrients, it was of interest 
to establish whether the cells remained viable. In 3-d cultures of spheroids of 10,000 or 
25,000 hMSCs, almost 90% of the harvested cells were viable as assayed by PI uptake 
and labeling with annexin V-FITC (Fig. III.2A). The number of apoptotic or necrotic 
cells was greater in spheroids prepared with 100,000 or 250,000 hMSCs (Fig. III.2A). 
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Also, the number of apoptotic or necrotic cells increased slightly when the incubation 
period was extended from 3 d to 4 d (Fig. III.2B). 
 
III.3.3. Analysis of spheroid hMSC size in vitro and relative tissue distribution after i.v. 
infusion 
As suggested by histological sections (Fig. III.1B), hMSCs in spheroids appeared 
smaller than hMSCs from standard monolayer cultures. The cells released from 
spheroids by trypsinization were nearly half the diameter and approximately one-fourth 
the volume of hMSCs derived from adherent monolayers as shown by flow cytometry 
(Fig. III.3 and Fig. III.4A) and microscopy (Fig. III.4B). 
To test if the smaller size of the hMSCs dissociated from spheroids would allow 
the cells to traffic through the lung microvasculature and therefore distribute more 
efficiently into other tissues, both monolayer and spheroid hMSCs were injected i.v. into 
the tail vein of NOD/scid mice. Real-time PCR for human Alu sequences in the lungs 
collected 15 min after hMSC infusion suggested that the number of trapped cells 
decreased by about 25% with spheroid derived hMSCs compared with monolayer 
hMSCs, At the same time, a larger fraction of infused spheroid hMSCs were recovered 
in the liver, spleen, kidney, and heart (Fig. III.4C). 
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Figure III. 3. Analysis of spheroid derived hMSC size by flow cytometry. Flow cytometric determination 
of hMSC size from 3-d cultures of adherent monolayers (Adh High) or spheroids (Sph 25k) labeled with 
the viability dyes calcein AM (live cells, blue) and 7AAD (dead cells, red). (A) Representative log 
fluorescent dot plots. (B) Histogram of bead standards with diameters of 3, 7, 15, and 25 µm. (C) 
Representative linear scatter plots of the calcein AM+/7AAD− cell populations. Brackets were applied to 
the scatter plot at locations corresponding to the appropriate bead size (I = 0, J = 3 µm, K = 7 µm, L = 15 
µm, and M = 25 µm). Assays were performed at the same voltages. Bartosh et al., PNAS (2010) [198]. 
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Figure III. 4. Size analysis and i.v. infusion of spheroid hMSCs. (A) Assays of cell size by flow cytometry 
(n = 3). hMSC sizes were estimated from forward scatter (FS) (Inset) properties of the viable population 
(calcein AM+/7AAD−) relative to beads with known diameters (3, 7, 15, and 25 µm). (B) Cell size assayed 
by microscopy. (C) Relative tissue distribution of i.v. infused hMSCs. NOD/scid mice were infused i.v. 
with 106 monolayer or spheroid derived hMSCs. After 15 min, tissues were harvested for genomic DNA 
and tissue distribution of hMSCs was determined with real-time PCR for human Alu and GAPDH (n = 4–
5) and shown as relative to Adh High sample. *P < 0.05, **P < 0.01, and ***P < 0.001. Values are mean ± 
SD. Abbreviations: as in Fig. 1. Bartosh et al., PNAS (2010) [198]. 
 
 
 
III.3.4. Human MSCs dissociated from spheroids retain the properties of adherent 
hMSCs 
Human MSCs dissociated from spheroids retained the ability to differentiate into 
mineralizing cells and adipocytes (Fig. III.5A and B). The dissociated cells expanded 
more slowly during an initial passage and then more rapidly than adherent hMSCs 
through four passages before reaching senescence at about the same number of 
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population doublings (Fig. III.5C and Fig. III.6A). In addition, the dissociated cells 
readily generated colonies (CFUs) when plated at clonal densities (Fig. III.5D and Fig. 
III.6B). Consistent with the data on rates of propagation (Fig. III.5C), the number of 
CFUs from spheroid cells was initially less than the number of CFUs from adherent 
cultures but was greater in later passages (Fig. III.5D and Fig. III.6B). The surface 
epitopes of the hMSCs dissociated from spheroids were similar to the surface epitopes of 
hMSCs from adherent monolayers when dissociated under the same conditions with 
trypsin (10 min at 37 °C): the dissociated cells were negative for hematopoietic markers, 
and they were slightly less positive for CD73, CD90, and CD105, apparently because of 
the smaller size of the cells (Fig. III.5E, Figs. III.7–9, and Table III.1). 
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Figure III. 5. Spheroid hMSCs retain the properties of hMSCs from adherent cultures. (A) Differentiation 
of hMSCs in osteogenic medium (Osteo Dif) and control medium (Osteo Con). Cultures were stained with 
Alizarin Red after 14 d. (Scale bar, 200 µm.) (B) Differentiation of hMSCs in adipogenic medium (Adipo 
Dif) and control medium (Adipo Con). Cultures were stained with Oil Red O after 14 d. (Scale bar, 200 
µm.) (C) Growth of hMSCs (donor 2) as monolayers from high density and hanging drop cultures plated at 
low density (5,500 cells/plate) and passaged every 7 d (n = 4). Cumulative population doublings (PDs) 
after each passage are shown (Inset). (D) CFU-F assays of hMSCs (donor 2) plated at 83 cells/plate and 
incubated for 14 d (n = 4). Representative plates at passage 1 and passage 2 after transfer. Values are mean 
± SD. (E) Flow cytometry of surface protein expression on hMSCs. Abbreviations: as in Fig. 1 with P1 to 
P10 indicating passage number. Bartosh et al., PNAS (2010) [198]. 
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Figure III. 6. hMSCs from spheroids exhibit similar growth characteristics and clonogenicity to monolayer 
cultures. (A) Growth of hMSCs (donor 1) as monolayers from high density and hanging drop cultures 
plated at low density (5,500 cells/plate) and passaged every 7 d. Cumulative population doublings (PDs) 
after each passage are shown (Inset). (B) CFU-F assays of hMSCs (donor 1) plated at 83 cells/plate and 
incubated for 14 d. Representative plates at passage 1 and passage 2 after transfer. Values are mean CFU-
F percentage ± SD (n = 4). Bartosh et al. PNAS (2010) [198]. 
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Figure III. 7. Surface phenotype of hMSCs cultured as monolayers at low cell density. Flow cytometry 
measurements of characteristic hMSC surface proteins. Passage 2 hMSCs were plated at 100 cells/cm2 and 
grown for 7 d until approximately 70% confluent before analysis. The cells were harvested by incubation 
with trypsin/EDTA for 5 min. Bartosh et al. PNAS (2010) [198]. 
 
 
 
 
 
 
 
Fig. S3. Surface phenotype of hMSCs cultured as monolayers at low cell density. Flow cytometry measurements of characteristic hMSC surface proteins.
Passage 2 hMSCs were plated at 100 cells/cm2 and grown for 7 d until approximately 70% confluent before analysis. The cells were harvested by incubation
with trypsin/EDTA for 5 min.
Bartosh et al. www.pnas.org/cgi/content/short/1008117107 6 of 11
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Figure III. 8. Surface phenotype of hMSCs cultured as monolayers at high cell density and harvested by 
incubation with trypsin for 10 min. Flow cytometry measurements of characteristic hMSC surface 
proteins. Passage 3 hMSCs were plated at 5,000 cells/cm2 and grown for 3 d before analysis. The cells 
were harvested by incubation with trypsin/EDTA for 10 min. Bartosh et al. PNAS (2010) [198]. 
 
 
 
Fig. S4. Surface phenotype of hMSCs cultured as monolayers at high cell density and harvested by incubation with trypsin for 5 min. Flow cytometry
measurements of characteristic hMSC surface proteins. Passage 3 hMSCs were plated at 5,000 cells/cm2 and grown for 3 d before analysis. The cells were
harvested by incubation with trypsin/EDTA for 5 min.
Fig. S5. Surface phenotype of hMSCs cultured as monolayers at high cell density and harvested by incubation with trypsin for 10 min. Flow cytometry
measurements of characteristic hMSC surface proteins. Passage 3 hMSCs were plated at 5,000 cells/cm2 and grown for 3 d before analysis. The cells were
harvested by incubation with trypsin/EDTA for 10 min.
Bartosh et al. www.pnas.org/cgi/content/short/1008117107 7 of 11
  66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III. 9. Surface phenotype of hMSCs derived from spheroids. Flow cytometry measurements of 
characteristic hMSC surface proteins. Passage 3 hMSCs were suspended in hanging drops at 25,000 
cells/drop and cultured for 3 d before analysis. The spheroids were dissociated for 10 min with 
trypsin/EDTA to obtain the spheroid cells. Bartosh et al. PNAS (2010) [198]. 
 
 
 
 
 
Fig. S6. Surface phenotype of hMSCs derived from spheroids. Flow cytometry measurements of characteristic hMSC surface proteins. Passage 3 hMSCs were
suspended in hanging drops at 25,000 cells/drop and cultured for 3 d before analysis. The spheroids were dissociated for 10 min with trypsin/EDTA to obtain the
spheroid cells.
Fig. S7. Cell cycle analysis of monolayer and spheroid hMSCs. Representative cell cycle distribution in hMSCs for donor 1 grown at low density (A), at high
density (B), and as spheroids (C) was determined by analyzing DNA content of permeabilized hMSCs labeled with PI. DNA content was measured with a flow
cytometer and data analyzed using MultiCycle software. (D) Summary of the cell cycle analysis data. Values are mean ± SD (n = 3).
Bartosh et al. www.pnas.org/cgi/content/short/1008117107 8 of 11
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Table III. 1. List of antibodies used to detect the expression of cell surface proteins in hMSC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total of nine different protocols were run for each hMSC sample to determine the surface proteins 
expressed. Bartosh et al. PNAS (2010) [198]. 
 
 
Table S1. List of antibodies used to detect the expression of cell surface proteins in hMSCs
Protocol Protein Fluorochrome Isotype Clone Manufacturer
Protocol 1 CD36 FITC Ms IgG-1 FA6.152 Beckman-Coulter
CD34 PE Ms IgG-1 581 Beckman-Coulter
CD19 ECD Ms IgG-1 J3.119 Beckman-Coulter
CD11b PE-Cy5 Ms IgG-1 Bear1 Beckman-Coulter
CD45 PE-Cy7 Ms IgG-1 J.33 Beckman-Coulter
Protocol 2 PCLP1 FITC Ms IgG-2a 53D11 MBL International
CD166 PE Ms IgG-1 3A6 Beckman-Coulter
CD90 PE-Cy5 Ms IgG-1 Thy1/310 Beckman-Coulter
Protocol 3 CD49b FITC Ms IgG-1 Gi9 Beckman-Coulter
CD105 PE Ms IgG-3 IG2 Beckman-Coulter
CD184 APC Ms IgG-2a 12G5 BD Biosciences
CD3 PE-Cy7 Ms IgG-1 UCHT1 Beckman-Coulter
Protocol 4 CD147 FITC Ms IgG-1 HIM6 BD Biosciences
CD49c PE Ms IgG-1 C3 II.1 BD Biosciences
CD29 PE-Cy5 Ms IgG-1 MAR4 BD Biosciences
Protocol 5 CD59 FITC Ms IgG-2a P282E Beckman-Coulter
CD146 PE Ms IgG-2a TEA1/34 Beckman-Coulter
CD79a PE-Cy5 Ms IgG-1 HM47 Beckman-Coulter
Protocol 6 Class I HLA FITC Ms IgG-1 G46-2.6 BD Biosciences
CD271 PE Ms IgG-1 C40-1457 BD Biosciences
CD49f PE-Cy5 Rat IgG-2a GoH3 BD Biosciences
CD117 PE-Cy7 Ms IgG-1 104D2D1 Beckman-Coulter
Protocol 7 Class II HLA FITC Ms IgG-2a TU39 BD Biosciences
CD73 PE Ms IgG-1 AD2 BD Biosciences
CD106 PE-Cy5 Ms IgG-1 51–10C9 BD Biosciences
Protocol 8 HGFR FITC Rat IgG-1 eBioclone97 eBioscience
CD49d PE Ms IgG-1 9F10 BD Biosciences
CD14 ECD Ms IgG-2a RMO52 Beckman-Coulter
CD44 APC Ms IgG-2b G44-26 BD Biosciences
Protocol 9 Isotypes FITC Ms IgG-1 679.1Mc7 Beckman-Coulter
PE Ms IgG-2a 7T4-1FS Beckman-Coulter
FITC Ms IgG-2a G155-178 BD Biosciences
FITC Rat IgG-1, k eBioscience
PE Ms IgG-1, k MOPC-31C BD Biosciences
PE Ms IgG-3 Santa Cruz
ECD Ms IgG-1 679.1MC7 Beckman-Coulter
ECD Ms IgG -2a 7T4-1F5 Beckman-Coulter
PE-Cy5 Ms IgG-1 679.1Mc7 Beckman-Coulter
PE-Cy5 Rat IgG-2a R35-95 BD Biosciences
APC Ms IgG-2a 7T4-1F5 Beckman-Coulter
APC Ms IgG-2b 27–35 BD Biosciences
PE-Cy7 Ms IgG-1 679.1Mc7 Beckman-Coulter
Total of nine different protocols were run for each hMSC sample to determine the surface proteins expressed.
Bartosh et al. www.pnas.org/cgi/content/short/1008117107 10 of 11
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III.3.5. Transcriptome changes in the spheroid hMSCs 
Surveys with microarray assays demonstrated that 236 genes were upregulated 
and 230 genes were downregulated in a comparison of spheroid cells with hMSCs from 
adherent monolayers (Fig. III.10A and Table III.2). There were increases in genes with 
ontologies for extracellular region, regulation of cell adhesion, receptor binding, cell 
communication, extracellular matrix, and negative regulation of cell proliferation (Fig. 
III.10A). Also, there were parallel decreases in genes with ontologies for cytoskeleton 
organization and biogenesis, mitosis, cell cycle, and extracellular matrix (Fig. III.10A). 
Of special interest was the increase in genes with ontologies for response to wounding 
and inflammatory response (Fig. III.10A). Real-time RT-PCR assays (Fig. III.11A) 
demonstrated marked increases in the expression of TSG-6; STC-1, an anti-
inflammatory/anti-apoptotic protein; leukemia inhibitory factor (LIF), a cytokine for 
growth and development; IL-24, a tumor suppressor protein; TRAIL, a protein with 
selectivity for killing certain cancer cells; and CXCR4, a receptor involved in MSC 
homing. As expected from its stimulatory effect of MSC proliferation [206], there was 
decreased expression of DKK1, an inhibitor of Wnt signaling (Fig. III.11A).  
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Figure III. 10. Microarray assays of hMSCs from two donors. (A) Hierarchical clustering of differentially 
expressed genes. Genes that were either up (236 genes) or downregulated (230 genes) in spheroids (Sph 
25k) at least twofold compared with their adherent culture counterparts (Adh Low and Adh High), were 
used in hierarchical clustering. The most significant Gene Ontology terms for upregulated genes (red) and 
downregulated genes (blue) are shown next to the heat map. (B) Flow cytometry of differentially 
expressed surface epitopes on hMSCs. Abbreviations: as in Fig. 1. Bartosh et al. PNAS (2010) [198]. 
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Table III. 2. Selected genes upregulated in hMSC spheroids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are fold changes of 25k Sph sample compared with either Adh Low or Adh High for two donors. 
Bartosh et al. PNAS (2010) [198]. 
Table S2. Selected genes up-regulated in hMSC spheroids
Gene (GeneID)
Donor 1 Donor 2
25k Sph vs.
Adh Low
25k Sph vs.
Adh High
25k Sph vs.
Adh Low
25k Sph vs.
Adh High
Secreted molecules
IL8 (3576) 78 82 38 34
TSG-6 (7130) 55 61 51 40
IL1B (3553) 3 24 19 12
BMP2 (650) 16 14 23 12
CXCL1 (2919) 14 12 7 3
SPP1 (6696) 13 12 4 5
GDF15 (9518) 12 6 17 6
IL11 (3589) 11 10 9 10
LIF (3976) 10 12 7 9
SMOC1 (64093) 10 8 6 4
IL1A (3552) 9 7 5 3
IGFBP5 (3488) 8 11 11 14
C1S (716) 8 4 9 3
BMP6 (654) 7 8 3 4
TRAIL (8743) 7 7 11 6
PTHLH (5744) 6 6 3 3
NMB (4828) 6 5 5 3
APOD (347) 6 5 7 3
PLTP (5360) 6 7 5 4
IL24 (11009) 6 6 10 7
IL6 (3569) 6 3 3 3
STC1 (6781) 6 7 6 10
NAMPT (10135) 5 5 3 3
Cell surface receptors
ITGA2 (3673) 26 23 13 18
EDNRA (1909) 21 15 7 9
GPR84 (53831) 18 13 11 5
BDKRB2 (624) 10 10 9 6
CXCR4 (7852) 7 7 4 5
DPP4 (1803) 7 6 5 4
CD82 (3732) 6 5 7 4
PLA2R1 (22925) 6 5 7 4
PTGDR (5729) 6 7 7 5
ICAM1 (3383) 5 6 8 5
COLEC12 (81035) 5 4 7 6
C3AR1 (719) 5 5 4 3
Extracellular matrix molecules
MMP13 (4322) 64 66 39 37
CHI3L1 (1116) 42 33 72 36
TFPI2 (7980) 25 55 15 53
MMP3 (4314) 14 15 9 6
MMP1 (4312) 10 11 25 16
ADAMTS5 (11096) 8 7 5 3
GPC6 (10082) 6 4 3 2
LUM (4060) 6 3 6 3
LAMA4 (3910) 5 3 5 3
Transcription factors
NR4A2 (4929) 11 12 13 10
ETV1 (2115) 10 11 6 6
MAFB (9935) 9 9 6 6
SATB1 (6304) 6 6 7 5
Values are fold changes of 25k Sph sample compared with either Adh Low or Adh High for two donors.
Bartosh et al. www.pnas.org/cgi/content/short/1008117107 11 of 11
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Figure III. 11. Spheroid hMSCs express high levels of anti-inflammatory and anti-tumorigenic molecules. 
(A) Real-time RT-PCR measurements for anti-inflammatory genes (TSG-6, STC-1, and LIF), anti-
tumorigenic genes (IL-24 and TRAIL), gene for an MSC homing receptor (CXCR4), and gene for the Wnt 
signaling inhibitor (DKK1) for two donors. Values are mean RQ ± 95% confidence interval from triplicate 
assays compared with Adh Low sample. (B) Images of high density monolayer (Adh High), spheroids 
(Sph 25k), and spheroid derived hMSCs (Sph 25k DC) 24 h after transfer onto adherent (Adh) or non-
adherent (Non adh) surfaces. Cultures were in six-well plates containing 1.5 mL CCM and either 200,000 
hMSCs from high density cultures, eight spheroids, or 200,000 hMSCs dissociated from spheroids. After 
24 h, medium was recovered for ELISAs and cells lyzed for protein assays. (Scale bar, 200 µm.) TSG-6 
(C), STC-1 (D), and LIF (E) ELISAs on medium, normalized to total cellular protein. Values are mean ± 
SD (n = 3). Abbreviations: as in Fig. 1 with ND indicating not detectable and Sph 25k DC-Adh indicating 
hMSCs dissociated from Sph 25k and plated on cell adherent surfaces. Bartosh et al., PNAS (2010) [198]. 
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III.3.6. Changes in cell surface protein expression and cell cycle distribution in hMSC 
spheroids 
Assays by flow cytometry demonstrated decreased expression of podocalyxin-
like protein (PODXL), an anticell-adhesion protein; and α4-integrin (CD49d), an 
integrin subunit associated with lymphocyte homing (Figs. III.7-9). There was partial 
downregulation of the melanoma cell adhesion molecule (MCAM or CD146) that is 
used as a marker for endothelial cells and pericytes, and of ALCAM (CD166), a cell 
adhesion molecule (Fig. III.10B). At the same time, there was increased expression of an 
integrin subunit for cell adhesion (α2-integrin of CD49b), and a protein associated with 
suppression of metastases (CD82) (Fig. III.10B). As expected from microarray results, 
assays by flow cytometry also demonstrated a decrease of spheroid hMSCs in S-phase 
compared with monolayer hMSCs (Fig. III.12A–D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III. 12. Cell cycle analysis of monolayer and spheroid hMSCs. Representative cell cycle 
distribution in hMSCs for donor 1 grown at low density (A), at high density (B), and as spheroids (C) was 
determined by analyzing DNA content of permeabilized hMSCs labeled with PI. DNA content was 
measured with a flow cytometer and data analyzed using MultiCycle software. (D) Summary of the cell 
cycle analysis data. Values are mean ± SD (n = 3). Bartosh et al. PNAS (2010) [198]. 
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III.3.7. Spheroid hMSCs secrete anti-inflammatory proteins 
Spheroids of hMSCs plated on adherent culture surfaces gradually generated 
spindle-shaped cells that migrated away from the spheroids (Fig. III.11B). No migration 
was seen with spheroids plated on non-adherent surfaces (Fig. III.11B). ELISAs 
demonstrated that hMSCs either in spheroids or dissociated from spheroids continued to 
secrete TSG-6, STC-1, and LIF when plated on culture dishes for 24 h (Fig. III.11C–E). 
The levels of all three factors were much higher than with adherent monolayer hMSCs. 
About the same levels of STC-1 and LIF were observed in spheroids cultured directly 
either on adherent or non-adherent plates, but spheroids cultured on non-adherent dishes 
secreted more TSG-6 (Fig. III.11C–E). The levels of TSG-6, STC-1, and LIF decreased 
when the hMSCs were dissociated from spheroids and cultured on adherent plates but 
the levels remained much higher than with adherent monolayers (Fig. III.11C–E). 
 
III.3.8. Spheroid hMSCs decrease activation of macrophages in vitro and inflammation 
in vivo 
The increased secretion of anti-inflammatory molecules TSG-6 and STC-1 by the 
spheroid hMSCs suggested that the cells would be more effective than adherent 
monolayer cultures of hMSCs in reducing inflammatory responses. To test this 
prediction, mouse macrophages were preactivated with LPS in the upper chamber of a 
transwell, followed by a transfer of the chamber to a test well (Fig. III.13A). Under the 
conditions of the experiment, the presence in the test well of hMSCs from adherent 
monolayers had no significant effect on the expression or secretion of TNFα by the 
stimulated macrophages (Fig. III.13B and Fig. III.14A). In contrast, TNFα expression 
and secretion was decreased significantly by the presence in the test well of intact 
spheroids or hMSCs dissociated from spheroids (Fig. III.13B and Fig. III.14A). The 
results indicated therefore that the spheroid derived hMSCs secreted more effective anti-
inflammatory factors. 
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Figure III. 13. hMSC spheroids exhibit enhanced anti-inflammatory effects in vitro and in vivo. (A) 
Schematic of the mouse macrophage (mMΦ) assay. mMΦs were seeded in the upper chamber of a 
transwell, stimulated with LPS for 90 min, the LPS was removed, and the chamber transferred to a six-
well dish plated with monolayer (Adh), spheroid (Sph), or spheroid derived hMSCs (Sph DC) at the same 
cell density. MΦ:hMSC (2:1). After 5 h, medium was collected for ELISAs. (B) ELISA for mTNFα in 
medium from cocultures (n = 3). (C–F) Anti-inflammatory activity of hMSCs in a mouse model of 
peritonitis. C57BL/6 mice were injected i.p. with zymosan to induce inflammation. After 15 min, the mice 
were injected i.p. with 1.5 × 106 monolayer hMSCs, 60 spheroids, or 1.5 × 106 spheroid derived cells. 
After 6 h, peritoneal lavage was collected and mTNFα (C), mMPO (D), and mCXCL2 (E) levels were 
determined with ELISAs. Total amounts of the specific molecules in the lavage are shown (n = 4–8). After 
24 h, blood was collected and plasmin activity was measured from serum (n = 3–6). Values are mean ± 
SD. Not significant (NS) P ≥ 0.05, *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations: as in Figs. 1 
and 6. Bartosh et al. PNAS (2010) [198]. 
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Figure III. 14. hMSC spheroids show increased anti-inflammatory effects in vitro and in vivo. (A) Real-
time RT-PCR assays of RNA for mouse TNFα in mouse macrophages (MΦs). MΦs were seeded in the 
upper chamber of a transwell, stimulated with LPS for 90 min, the LPS was removed, and the chamber 
transferred to a six-well dish plated with monolayer (Adh), spheroid (Sph), or spheroid derived (Sph DC) 
hMSCs at equal cell density. MΦ:hMSC (2:1). After 5 h, MΦs were lyzed, RNA was isolated, and mTNFα 
expression was determined with real-time RT-PCR. Values are mean ± SD (n = 3) normalized to MΦ 
sample without LPS stimulation. (B–D) Anti-inflammatory activity of hMSCs in a mouse model of 
peritonitis. C57BL/6 mice were injected i.p. with zymosan to induce inflammation. After 15 min, the mice 
were injected i.p. with 1.5 × 106 monolayer hMSCs (Adh), 60 spheroids (Sph), or 1.5 × 106 spheroid 
derived cells (Sph DC). After 6 h, peritoneal lavage was collected and lavage protein content (B), volume 
(C), and mIL-1β (D) were determined. Values are mean ± SD (negative control, n = 4; vehicle control, n = 
6; Adh treated, n = 6; Sph treated, n = 8; Sph DC treated, n = 6). Not significant (NS) P ≥ 0.05, *P < 0.05, 
**P < 0.01, and ***P < 0.001. Bartosh et al. PNAS (2010) [198]. 
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To test the effects of spheroid hMSCs on inflammation in vivo, a mouse model 
of zymosan-induced peritonitis was used [207]. Six hours after i.p. administration of 
monolayer, spheroid, or spheroid derived hMSCs, inflammatory exudates were collected 
and used in estimating the level of inflammation. hMSC spheroids significantly 
decreased the protein content of the lavage fluid (Fig. III.14B) and the volume (Fig. 
III.14C), neutrophil activity, as assayed by secreted MPO (Fig. III.13D), and levels of 
the pro-inflammatory molecules TNFα (Fig. III.13C), CXCL2 (Fig. III.13E), and IL-1β 
(Fig. III.14D). In addition, serum levels of plasmin activity, an inflammation associated 
protease that is inhibited by TSG-6 [62], were decreased significantly by hMSC 
spheroids (Fig. III.13F). Serum plasmin activity was reduced approximately to the levels 
of non-inflammatory control animals 24 h after spheroid injection (Fig. III.13F). 
Spheroid derived hMSCs also substantially decreased levels of the inflammatory 
markers assayed, although to a lesser extent than intact spheroids (Fig. III.13C–F and 
Fig. III.14B–D). Moreover, hMSC spheroids were significantly more effective than 
adherent monolayer hMSC in suppressing inflammation (Fig. III.13C–F and Fig. 
III.14B). 
 
III.4. Discussion  
Classically hMSCs were isolated and expanded as adherent monolayer cultures, 
but it was soon recognized that centrifugation of the cells to form micropellets or large 
aggregates greatly enhanced their chondrogenic differentiation that slowly occurred over 
several weeks [191,208]. However, several recent publications demonstrated that culture 
of MSCs in 3D or as spheroids for shorter periods of time improved their therapeutic 
potential by increased expression of genes such as CXCR4 to promote adhesion to 
endothelial cells or of IL-24 that has tumor suppressing properties [193,194,203]. The 
experiments presented here were designed to prepare hMSCs as spheroids that 
maximally expressed TSG-6, the anti-inflammatory protein that produced beneficial 
effects in mice with myocardial infarcts because it was expressed at high levels after i.v.-
infused hMSCs were trapped in the lung [51]. 
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The results demonstrated that the properties of hMSCs cultured as spheroids 
depend critically on the experimental conditions. In hanging drops, the cells first formed 
a network and then most of the cells coalesced into a single spheroid. Optimal levels of 
TSG-6 expression were observed with spheroids approximately 500 µm in diameter and 
incubated for 3 d. Expression levels remained high but were lower in larger spheroids, 
and more of the cells became apoptotic or necrotic in the larger spheroids. Also, more of 
the cells became apoptotic or necrotic with longer times of incubation. The cells in 
spheroids retained most of the surface epitopes of hMSCs from adherent cultures. Also, 
hMSCs dissociated from spheroids retained the potential to differentiate into 
mineralizing cells and adipocytes. They also expanded at a similar rate as hMSCs from 
adherent monolayer cultures after a delay through one passage. In addition, spheroid- 
dissociated hMSCs remained highly clonogenic.  
As was observed previously with large hMSC spheroids [192] and hMSCs in 3D 
culture [203], surveys with mRNA/cDNA microarrays demonstrated marked differences 
in the transcriptomes compared with hMSCs from adherent cultures. Quantitative assays 
confirmed some of the important differences. As expected, there was a marked decrease 
in the anticell-adhesion protein PODXL [204] and a decrease in cell cycling. Of special 
note was that several of the differences had important implications for the potential 
therapeutic uses of hMSCs. There were higher levels of expression of the anti-
inflammatory protein TSG-6 than previously observed by preincubation of hMSCs with 
TNFα [51]. Also, there was a high level of expression of STC-1, a protein with both 
anti-inflammatory and anti-apoptotic effects [67,135]. The high levels of expression of 
both TSG-6 and STC-1 were maintained for at least 1 d after the cells were dissociated 
from the spheroids. Therefore the results suggested that both spheroids and spheroid 
derived hMSCs may be more effective than hMSCs from adherent cultures in 
modulating inflammatory reactions. The suggestion was confirmed by the demonstration 
that the spheroids and spheroid derived hMSCs were more effective in suppressing 
TNFα production by LPS-stimulated macrophages in culture. In addition, they were 
more effective in suppressing inflammation in an in vivo model for zymosan-induced 
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peritonitis. Also of special interest was that the spheroid hMSCs expressed high levels of 
transcripts for the tumor suppressor protein IL-24, an observation made previously with 
3D cultures of hMSCs prepared using spinner flasks and a rotating wall vessel bioreactor 
[203]. In addition, the spheroid hMSCs prepared under the conditions optimized to 
express TSG-6 also expressed high levels of transcripts for TRAIL that is selective for 
killing certain cancer cells [209,210] and for CD82 that suppresses some metastases 
[211]. Therefore, spheroids and spheroid derived hMSCs may be particularly effective as 
an adjunct therapy for some types of cancers, particularly for therapy of cancers 
sensitive to anti-inflammatory agents such as aspirin or steroids [212]. A further 
advantage of the spheroid hMSCs was that they were less than one-fourth the volume of 
hMSCs from adherent cultures. Therefore a significantly smaller number was trapped in 
the lung after i.v. infusion and thus larger numbers were found in many tissues [51,204]. 
The molecular forces that increase expression of anti-inflammatory and anti-
tumorigenic genes in hMSCs assembled into spheroids are intriguing but unclear. Cells 
in spheroids are in close association with each other and probably signal cues to each 
other much easier than in monolayer cultures, where only a very small part of the cell 
can touch another cell and secreted molecules must be present in high amounts to ensure 
communication. The changes in the hMSCs as they form spheroids are probably the 
result of the non-adherent culture conditions, high degree of confluency, nutrient 
deprivation, air-liquid interface, and “microgravity” of hanging drops. More detailed 
studies of each of these and other possible factors must be conducted to have a better 
understanding of the changes hMSCs accrue when they aggregate into spheroids. 
The results presented here indicated that hMSCs can be activated non-chemically 
in hanging drops to secrete substantial quantities of potent anti-inflammatory proteins 
and express anti-tumorigenic molecules. Therefore spheroid hMSCs may have 
advantages for many therapeutic applications. In addition, hMSCs dissociated from 
spheroids provide extremely small activated cells that could have major advantages for 
i.v. administration. 
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CHAPTER IV  
MANUSCRIPT 2: 
STANNIOCALCIN-1 SUPPRESSES MACROPHAGE RESPONSE TO DANGER 
SIGNALS BY REDUCING CD14 EXPRESSION AND ATTENUATES 
ISCHEMIC CARDIAC INJURY 
 
Stanniocalcin-1 (STC-1) is a multifunctional glycoprotein that ameliorates 
inflammation and tissue injury by reducing oxidative stress. Cardiomyocyte necrosis in 
the ischemic heart generates ‘danger’ signals that trigger an often detrimental 
inflammatory reaction involving monocyte recruitment and differentiation. Therefore, 
we evaluated the effects of recombinant STC-1 (rSTC-1) on monocyte fate and in a 
mouse model of myocardial infarction. Using an established protocol to differentiate 
human monocytes to macrophages, we demonstrated that rSTC-1 did not alter 
macrophage morphology or expression of the monocyte/macrophage marker CD11b and 
toll-like receptor (TLR) 4. However rSTC-1 treatment prior to monocyte differentiation 
decreased expression of the TLR4 co-receptor CD14 and levels of TNFα, CXCL2, and 
CCL2 produced by the differentiated cells in response to the TLR4 ligand 
lipopolysaccharide. Moreover, rSTC-1 treatment reduced CD14 expression in 
monocytes stimulated with endogenous danger signals, and in the ischemic mouse heart.  
Intravenous administration of rSTC-1 also suppressed levels of IL-1β and MPO, and 
formation of scar tissue in the infarcted heart while enhancing cardiac function.  The 
data suggests that one of the beneficial effects of STC-1 might be attributed to 
suppression of CD14 on recruited monocytes/macrophages that limits their inflammatory 
response.  STC-1 may be a promising therapy to protect the heart and other tissues from 
ischemic injury. 
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IV.1.  Introduction  
STC-1 is a conserved glycoprotein with an unusual history both in terms of its 
evolution and as a subject for biological research [69,70,110]. STC-1, formerly called 
hypocalcin, was named after it was discovered to be secreted by the corpuscles of 
Stannius, small endocrine glands that were found in bony fish and that were initially 
assumed to be adrenal glands because of their location on the ventral surface of the 
kidneys. However, surgical removal of the glands caused toxic hypercalcemia and led to 
the finding that STC-1 is a critical regulator of plasma calcium and phosphate 
homeostasis in the fishes. This role has since been replaced in mammals by parathyroid 
hormone, calcitonin, and 1, 25-dihydroxyvitamin D [70]. Instead, STC-1 in mammals is 
produced by a variety of tissues and has been proposed to regulate a variety of 
physiological and cellular functions in a paracrine/intracrine fashion.  A major 
intracellular target for STC-1 is mitochondria, the organelle also targeted by other 
intracrines such as angiotensin II, TGF-β, growth hormone, atrial natriuretic peptide, and 
Wnt 13 [69]. Binding sites for STC-1 have been identified on cell membrane fractions 
and on mitochondria [118], but the major effects of STC-1 have been difficult to define. 
Some observations demonstrated that STC-1 reversibly inhibits transmembrane calcium 
currents through L-type channels in cardiomyocytes [140] and decreases cytokine-
induced intracellular calcium signals in macrophages [147] suggesting that it has a 
continuing but diminished role in calcium metabolism. Other observations emphasized 
that STC-1 increases expression of mitochondrial UCPs that dissipate the proton 
gradient and thereby effectively uncouple oxidation from phosphorylation [142,143]. 
The increase in UCPs reduces the surge of ROS that is often seen with tissue injury and 
appears to explain, at least in part, the anti-inflammatory and anti-apoptotic properties of 
STC-1 in mouse models of sepsis [152], glomerulonephritis [135], and retinal 
degeneration [151]. The decrease in ROS production also appears to explain some of the 
effects of STC-1 in altering macrophage function [186], and protecting cardiac myocytes 
from angiotensin II-mediated injury [145]. However, the role of STC-1 on macrophage 
differentiation and in ischemic myocardial injury has not been studied. 
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Myocardial infarction is a leading cause of morbidity and mortality worldwide 
despite advances in therapy [195,197]. Myocardial tissue injury induces the release of 
endogenous inflammatory mediators or ‘danger’ signals including cytokines, ROS, and 
numerous intracellular factors that are inaccessible to the immune system but that are 
liberated from necrotic cells [197]. TLRs are among the cellular receptors that sense 
many danger signals released by necrotic cells and provide a key molecular link between 
tissue injury and inflammatory response [195]. A growing body of evidence suggests 
that inflammation after ischemic cardiac injury, especially when persistent, can 
exacerbate pathological remodeling of the heart and promote heart failure; therefore, 
strategies to regulate inflammatory pathways will improve prognosis after myocardial 
infarction [196,197]. 
Accordingly in the present report, we tested the hypotheses that STC-1 regulates 
macrophage phenotype and response to inflammatory mediators, reduces inflammation 
in the post-infarcted heart, and protects the heart from damage associated with ischemic 
injury. 
 
IV.2. Material and Methods 
 
IV.2.1. Cell culture 
The human monocyte cell line U937 was purchased from American Type Culture 
Collection (ATCC, Rockville, MD). The cells were cultured in a humidified atmosphere 
at 37°C and 5% (v/v) CO2 in macrophage medium consisting of RPMI-1640 (ATCC) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Atlanta 
Biologicals, Flowery Branch, GA), 100 units/ml penicillin and 100 µg/ml streptomycin 
(Gibco, Grand Island, NY).  
 
IV.2.2. Monocyte differentiation assay 
To induce macrophage differentiation of U937 monocytes, the cells were 
suspended at 500,000 cells/ml in petri dishes (VWR international, Radnor, PA) and 
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stimulated for 48 hours with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA, 
Sigma-Aldrich, St. Louis, MO). In separate experiments, U937 cells were stimulated 
concurrently with 5 µg/ml recombinant human HMGB1 (R&D systems, Minneapolis, 
MN) and recombinant human TNFα, IL-1β, and IL-6 (10 ng/ml each, R& D Systems).  
Differentiation assays were performed in the presence or absence of 1.0 µg/ml of human 
rSTC-1 (BioVendor Research and Diagnostic Products, Asheville, NC or Czech 
Republic). After 48 hours, images of the cells were captured on a Nikon Eclipse Ti-S 
inverted microscope using a Ds-Fi1 camera (Nikon, Melville, NY) and managed with 
NiS Elements AR 3.0 software (Nikon). The differentiated macrophages were 
subsequently harvested, counted, and processed for real-time RT-PCR or flow cytometry 
analysis. 
 
IV.2.3. In vitro inflammatory assay 
U937 monocytes stimulated for 48 hours with PMA (in the presence or absence 
of rSTC-1) were seeded at 600,000 cells/ml into 24-well culture plates (Corning 
Incorporated, Corning, NY). After a 3 hour recovery period, 50 ng/ml of LPS (Sigma-
Aldrich) was added to the cultures. In some experiments cultures of differentiated 
macrophages were treated with 1.0 µg/ml rSTC-1 just prior to LPS stimulation. Five 
hours later, CM of unstimulated or LPS-stimulated macrophages were collected. Cells 
and debris were removed from the CM by centrifugation at 500 x g for 5-10 minutes. 
Several aliquots were prepared from the CM and stored at -80°C until they were used for 
ELISA. 
 
IV.2.4. Ischemic cardiac injury model 
The experimental protocols were approved by the Institutional Animal Care and 
Use Committee of Texas A&M University Health Science Center and in accordance 
with guidelines set forth by the National Institutes of Health. Male immunodeficient 
NOD/scid mice (NOD.CB17-Prkdcscid/J, Jackson Laboratory, Bar Harbor, Maine), 7–8 
weeks of age and 25-30 grams of body weight, were used for this study to reduce the 
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immune reaction to human protein. The mice were kept on a 12 hour light-dark cycle 
and were provided sterile food and water ad libitum. To induce ischemic cardiac injury, 
mice were mechanically ventilated and maintained under anesthesia with isoflurane 
(1.5%, v/v) during the course of the procedure. The thoracic cavity was opened via an 
incision made at the left 5th intercostal space to visualize the left anterior descending 
coronary artery (LAD). An 8-0 prolene suture (Ethicon, Somerville, NJ) was positioned 
around the LAD distal to the first diagonal branch and permanently tied. After 
myocardial infarction was confirmed by ventricular blanching, the chest was closed.  
rSTC-1 (2.0 mg/kg body weight) in 0.9% (w/v) sodium chloride (Sigma-Aldrich) or 
equal volume of saline was injected intravenously 1 hour and 24 hours after ligation. To 
alleviate post-operative discomfort, buprenorphine (0.1 mg/kg) was administered 
subcutaneously twice daily for up to 5 days.  For endpoint assays, the mice were 
euthanized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (8 mg/kg). 
Levels of inflammatory mediators in the heart were determined from cardiac tissue 
lysates prepared 48 hours after ligation. Cardiac function was evaluated on day 21 and 
mice were euthanized to determine infarct size. 
 
IV.2.5. Evaluation of cardiac function 
Cardiac ejection fraction was determined by transthoracic echocardiography 21 
days after ligation of the LAD (LLDCA) using a 30 MHz transducer supported by a 
Vevo 2100 ultrasound instrument (VisualSonics Inc., Toronto, Canada). The procedure 
was performed on mice under isoflurane anesthesia. Heart rate was maintained at 350-
400 beats per minute. Left ventricular ejection fraction (LVEF) was evaluated from 
parasternal long axis position. The average of two separate recordings containing 3 
consecutive cardiac cycles were used per animal to obtain the LVEF. 
 
IV.2.6. Infarct size measurement   
Measurements of infarct size were performed on hearts obtained 21 days after 
surgery. Hearts were perfused with 3-5 ml of saline, excised from the chest, and fixed in 
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10-15 ml of 10% (v/v) formalin (Sigma-Aldrich) to be processed for staining. Paraffin-
embedded heart samples were cut into 5 µm sections from the apex to the base.  Every 
20th section was stained with Masson Trichrome. Quantitative assays for infarct size 
were performed as described by Takagawa and colleagues [213]. Images of every fifth 
stained section covering both ventricles (total of 10 sections per heart) were acquired 
using a Photometrics Coolsnap HQ2 camera mounted on a Nikon Eclipse Ti-E inverted 
microscope (Nikon). NiS Elements AR 3.0 software (Nikon) was used to measure 
midline infarct length of heart.    
 
IV.2.7. Real-time RT-PCR  
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, Valencia, 
CA) with DNase I (RNase-Free DNase Sel, Qiagen) digestion step. The isolated RNA 
was quantified with nanodrop spectrophotometer (ThermoFisher Scientific, Rockford, 
IL) and converted to cDNA with High-Capacity cDNA RT Kit (Applied Biosystems, 
Technologies, Grand Island, NY). Real-time RT-PCR was performed in triplicate for 
expression of human GAPDH, CD11b (ITGAM), CD14, TLR2, and TLR4 using 
TaqMan® Gene Expression Assays (Applied Biosystems, Technologies) and TaqMan® 
Fast Master Mix (Life Technologies). Total of 20 ng of cDNA was used for each 20 µl 
reaction. Thermal cycling was performed with 7900HT System (Applied Biosystems, 
Technologies) by incubating the reactions at 95° C for 20 seconds followed by 40 cycles 
of 95° C for 1 second and 60° C for 20 seconds. Data were analyzed with Sequence 
Detection Software V2.3 (Applied Biosystems, Technologie) and relative quantitation 
(RQ)s were calculated with comparative critical threshold (Ct) method using RQ 
Manager V1.2 (Applied Biosystems, Life Technologies).  
 
IV.2.8. Enzyme-linked immunosorbent assay (ELISA) for markers of inflammation 
 Levels of the inflammatory mediators TNFα, CXCL2, and CCL2 were 
determined in cell-free U937 CM using commercially available ELISA Kits (TNFα and 
CCL2 were from R&D Systems and CXCL2 from Abnova, Taipei City, Taiwan). To 
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determine levels of inflammation in the heart, ventricular tissue was minced with 
surgical scissors, transferred to tissue extraction reagent I (Life Technologies) containing 
1x of Halt protease inhibitor cocktail (ThermoFisher Scientific), and homogenized using 
a PowerGen model 125 tissue grinder (ThermoFisher Scientific).  The lysates were 
centrifuged at 1,000 x g for 10 minutes 4°C.   The protein rich supernatant was 
transferred to new tubes and centrifuged at 12,000 x g for 10 minutes.  Several aliquots 
were prepared from the supernatants and stored at -80°C.  Protein concentration was 
determined with micro BCA protein assay kit (ThermoFisher Scientific) per 
manufacturer’s instructions. Levels of mouse MPO, CD14, and IL-1β were measured 
using commercially available ELISA Kits (CD14 and IL-1β were form R&D Systems 
and MPO from Hycult Biotech, Plymouth Meeting, PA). The optical density was 
determined on a plate reader (FLUOstarOmega; BMG Labtech) at an absorbance of 450 
nm with wavelength correction at 540 nm. Where appropriate, samples were diluted 
prior to running the assay so that the optical density detected for the sample fit within the 
standard curve of the ELISA kit. 
 
IV.2.9. Flow cytometry analysis 
Cell surface expression of CD11b and CD14 was determined by flow cytometry. 
U937 cells were suspended at 2,000 cells/µl in 100 µl of cold PBS (Gibco) containing 
2% (v/v) FBS and then incubated for 20 min with 20 µl of human Fc receptor binding 
inhibitor (Affymetrix eBioscience, San Diego, CA). Without washing, cell suspensions 
were labeled with 0.2 µg of fluorescein-conjugated antibodies to CD11b (Clone Bear1, 
Beckman Coulter, Brea, CA) or CD14 (Clone RMO52, Beckman Coulter) for 20 min at 
room temperature. Isotype matched antibodies were used as controls. After 2 washes in 
PBS, cells were again suspended in PBS containing 2% FBS and analyzed on an FC500 
flow cytometer (Beckman Coulter). A minimum of 10,000 events was examined from 
the viable cell population.  Data were analyzed using CXP Software (Beckman Coulter). 
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IV.2.10. Statistical analyses 
Unpaired two-tailed Student’s t-test was used to compare data sets consisting of 
two treatment groups. One-way ANOVA was used to calculate levels of significance 
between multiple groups. Statistical analysis was performed with Graphpad Prism 5 
software. 
 
IV.3. Results 
 
IV.3.1. Recombinant STC-1 modulates the inflammatory response of differentiated 
human monocytes in vitro 
  To evaluate the effects of rSTC-1 treatment on monocyte differentiation and 
inflammatory response, we modified an established protocol that uses the protein kinase 
C (PKC) activator PMA to promote the differentiation of U937 human monocytes into 
macrophages [214]. Here, U937 cells were stimulated with 100 ng/ml of PMA for 48 
hours in the presence or absence of 1 µg/ml rSTC-1. The differentiated U937 cells were 
harvested, re-plated, and activated with 50 ng/ml of LPS. Five hours later, CM of the 
macrophages were collected (Fig. IV.1A) and used to evaluate levels of inflammatory 
cytokines/chemokines. As shown, PMA-differentiated U937 cells secreted high levels of 
TNFα, CXCL2, and CCL2 in response to LPS (Figs. IV.1B-D).  Addition of rSTC-1 to 
the cultures prior to PMA treatment significantly reduced the secretion of these 
cytokines and chemokines (Figs. IV.1B-D). We then examined the effects of rSTC-1 on 
inflammatory response of newly differentiated macrophages.  In these experiments, 
U937 monocytes were first differentiated with PMA for 48 hours and then treated with 
rSTC-1 just prior to LPS stimulation (Fig. IV.1E). Secretion of TNFα, CXCL2, and 
CCL2 in response to LPS was unchanged by treatment with rSTC-1 when it was applied 
to the cultures after the cells were differentiated (Figs. IV.1F-H). These results indicate 
that rSTC-1 therapy, during monocyte differentiation but not after, suppresses 
macrophage r esponse to inflammatory stimuli. 
 
  87 
Figure IV. 1. Recombinant stanniocalcin-1 (rSTC-1) treatment, prior to monocyte differentiation but not 
after, suppressed the inflammatory response of macrophages to danger signals. (A) Schematic illustrating 
the strategy used to evaluate the effects of rSTC-1 pre-treatment on macrophage response to 
lipopolysaccharide (LPS). Human U937 monocytes were induced to differentiate into macrophages by 
treatment with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA) in the presence or absence of 1 µg/ml 
of rSTC-1. After 48 hours, differentiated macrophages were harvested, plated, and incubated for another 3 
hours. Then, macrophages were stimulated with 50 ng/ml of LPS. After 5 hours, media conditioned (CM) 
by unstimulated or LPS-stimulated macrophages were collected and used to evaluate changes in levels of 
secreted TNFα (B), CXCL2 (C), and CCL2 (D) by ELISA. (E) Schematic illustrating the strategy used to 
evaluate the effects of rSTC-1 on the response of differentiated macrophages to LPS. U937 monocytes 
were plated in macrophage medium supplemented with 100 ng/ml of PMA for 48 hours. Differentiated 
macrophages were harvested, re-plated, and incubated with or without 1 µg/ml of rSTC-1. After 3 hours, 
macrophages were stimulated with LPS for an additional 5 hours. The CM was collected, clarified by 
centrifugation and used to determine levels of TNFα (F), CXCL2 (G), and CCL2 (H) by ELISA. Values 
are presented as mean + SEM (n=3). Statistical significance was determined using ANOVA (B-D) or 
student’s t-test (F-H) (not significant, ns p≥ 0.05; ***p< 0.001). 
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IV.3.2. Recombinant STC-1 regulates the expression of surface markers on 
differentiating macrophages  
To explore the mechanism(s) that drive the inhibitory effects of rSTC-1 on 
differentiating monocytes, we evaluated phenotypic changes of U937 cells in response to 
PMA and rSTC-1. In these experiments, U937 cells were stimulated with PMA for 48 
hours in the presence or absence of rSTC-1 and then analyzed by microscopy, flow 
cytometry, and real-time RT-PCR (Fig. IV.2A). In culture, undifferentiated U937 
monocytes propagate in suspension as single cells that ultimately form adherent colonies 
in the presence of PMA (Fig. IV.2B).  Analysis by microscopy revealed that cells treated 
simultaneously with PMA and rSTC-1 shared a similar morphology to cells incubated 
with PMA alone (Fig. IV.2B). We next assayed for changes in expression of 
monocyte/macrophage surface markers by flow cytometry. We observed a dramatic 
increase in cell surface expression of CD11b and CD14 on PMA-differentiated 
macrophages (Fig. IV.2C). Interestingly, rSTC-1 treatment caused a marked reduction in 
cell surface expression of CD14 without changing CD11b levels (Fig. IV.2C). Since 
CD14 is a well-known co-receptor for TLR2 and TLR4 [176], we examined mRNA 
levels of these TLRs in addition to CD11b and CD14 by real-time RT-PCR. As 
expected, the expression of CD11b, CD14, TLR2, and TLR4 was increased in U937 
cells differentiated with PMA (Figs. IV.2D-G); however, we detected a notable decline 
in CD14 message levels after treatment with PMA and rSTC-1 (Fig. IV.2E) but did not 
detect significant effects of rSTC-1 on amount of CD11b and TLR4 mRNA (Figs. IV.2D 
and F). In contrast, the expression of TLR2 was significantly increased in U937 cells 
treated with rSTC-1 (Fig. IV.2G). These data suggest that rSTC-1 suppresses 
macrophage response to danger signals by attenuating the up-regulation of the TLR co-
receptor CD14 in differentiating macrophages.  
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Figure IV. 2. Expression of CD14 was reduced in differentiating monocyte/macrophages by treatment 
with recombinant stanniocalcin-1 (rSTC-1). Human U937 monocytes were incubated in macrophage 
medium supplemented with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA) in the presence or 
absence of 1.0 µg/ml of rSTC-1. After 48 hours, morphology of differentiated macrophages was evaluated 
by light microscopy. Then, macrophages were harvested and processed for real-time RT-PCR or flow 
cytometry analysis. (A) Schematic showing the workflow. (B) Representative images of undifferentiated 
U937 monocytes (No Treatment), PMA-differentiated U937 macrophages (PMA), and U937 cells 
stimulated with PMA and rSTC-1 (PMA+ rSTC-1). 10x magnification (C) Cell surface expression of 
CD11b and CD14 was assessed by flow cytometry. Real-time RT-PCR for CD11b (D), CD14 (E), TLR4 
(F), and TLR2 (G) in undifferentiated U937 monocytes and cells stimulated with PMA for 48 hours (with 
and without rSTC-1 treatment). Values are expressed as mean + SEM (n=3). Data was analyzed using 
ANOVA (not significant, ns p≥ 0.05, *p< 0.05, **p< 0.01, ***p< 0.001). 
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IV.3.3. The effect of rSTC-1 on CD14 is PMA independent 
To further explore the role of STC-1 on monocyte-to-macrophage differentiation, 
we evaluated the effects of rSTC-1 on expression of CD11b and CD14 in U937 
monocytes in response to numerous inflammatory stimuli classically associated with 
ischemic tissue injury. As shown, U937 cells were stimulated with a pro-inflammatory 
cocktail consisting of 5 µg/ml human HMGB1 and 10 ng/ml each of recombinant human 
TNFα, IL-1β, and IL-6 (Figs. IV.3A).  After 48 hours, differentiated macrophages were 
lysed to quantify mRNA levels of CD11b and CD14 by real-time RT-PCR.  The 
expression of CD11b was increased significantly after the cells were stimulated with the 
inflammatory cocktail in the presence and absence of rSTC-1 (Fig. IV.3B). In contrast, 
we observed a dramatic reduction in U937 cell expression of CD14 (Fig. IV.3C) similar 
to that observed previously with PMA treated cells. The data indicates that STC-1 
suppresses inflammatory response of newly differentiated macrophages driven by the 
ischemic tissue microenvironment, such as observed with myocardial infarction, by 
inhibiting CD14 expression. 
 
IV.3.4. CD14 expression and inflammatory response in the ischemic heart were 
diminished by intravenous administration of rSTC-1  
Based on our observations demonstrating the inhibitory effects of rSTC-1 on 
macrophage CD14 expression and response to LPS, we hypothesized that rSTC-1 
treatment reduces inflammation following acute myocardial infarction and protects the 
ischemic heart. For these experiments a myocardial infarct was generated in NOD/scid 
mice by permanent LLDCA and rSTC-1 was administered intravenously (2.0 mg/kg) 1 
hour and 24 hours after ligation. To study the effects of rSTC-1 on inflammation, the 
mice were euthanized 48 hours after surgery and the heart tissues were processed (Fig. 
IV.4A) for ELISA. The amount of CD14 protein was increased in heart lysates following  
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Figure IV. 3. Recombinant stanniocalcin-1 (rSTC-1) reduced CD14 expression in monocyte/macrophages 
stimulated with danger signals. Human U937 monocytes were stimulated with 5 µg/ml human high 
mobility group box1 (HMGB1) and 10 ng/ml each of recombinant human tumor necrosis factor alpha 
(TNFα), interleukin 1 beta (IL-1β), and IL-6 in the presence or absence of 1.0 µg/ml rSTC-1 treatment. 
After 48 hours, cells were lysed for real-time RT-PCR. (A) Schematic showing the workflow. The fold 
changes of mRNA levels for CD11b (B) and CD14 (C) were measured in unstimulated U937 monocytes, 
stimulated U937 monocytes, and stimulated cells treated simultaneously with rSTC-1. Values are 
expressed as mean + SEM (n=3). Data were analyzed with ANOVA (not significant, ns p≥ 0.05, *p< 0.05, 
**p< 0.01, ***p< 0.001).  
 
 
 
infarction. In a manner similar to our in vitro data using U937 cells, administration of 
rSTC-1 significantly reduced levels of CD14 protein (Fig. IV.4B). Moreover rSTC-1 
treatment reduced cardiac levels of MPO (Fig. IV.4C); a bio-marker of tissue injury that 
is produced mainly by activated neutrophils and macrophages, and that has powerful 
pro-oxidative and pro-inflammatory properties [197,215]. Since the life span of 
inflammatory cells can be prolonged in the pro-inflammatory environment due to the 
effects of several cytokine mediators such as IL-1β [216], we measured levels of IL-1β 
in the heart lysate. We observed that IL-1β amount was increased 48 hours after 
LLDCA; however, the amount of this cytokine was significantly reduced after rSTC-1 
treatment (Fig. IV.4D). Collectively, these data suggest that STC-1 suppresses levels of 
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inflammatory mediators in the heart following myocardial infarction and can protect 
cardiomyocytes from injury directly caused by MPO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV. 4. Intravenous administration of recombinant stanniocalcin-1 (rSTC-1) reduced the expression 
of CD14 in cardiac tissue and attenuated inflammation following myocardial infarction. NOD/scid mice 
were subjected to ischemic cardiac injury by permanent ligation of the left anterior descending coronary 
artery (LLDCA). At 1 hour and 24 hours after ligation, 2.0 mg/kg of rSTC-1 or equal volume of 0.9% 
sodium chloride (saline) was administered intravenously. Mice were euthanized 48 hours after LLDCA to 
collect heart tissue and assess inflammatory response. (A) Diagram showing the workflow of the cardiac 
injury model. Amounts of CD14 (B), myeloperoxidase (MPO) (C), and interleukin 1 beta (IL-1β) (D) were 
determined by ELISA on heart tissue lysates prepared 48 hours after LLDCA. Values are expressed as 
mean (n=4-9). Statistical significance was determined using student’s t-tests (* p< 0.05, ** p< 0.01). 
 
 
 
IV.3.5. Intravenous administration of rSTC-1 improves heart function and reduced scar 
formation in ischemic cardiac injury 
To examine the therapeutic effects of rSTC-1, myocardial infarction was induced 
in NOD/scid mice followed by 2 injections of rSTC-1 (2.0 mg/kg) as described 
previously. Changes in heart function were determined with echocardiography by 
measuring LVEF on anesthetized mice 21 days after LLDCA (Fig. IV.5A). The results 
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showed a substantial decrease in LVEF following coronary artery ligation that was 
improved significantly by treatment with rSTC-1 (Fig. IV.5B). After cardiac function 
was evaluated, the hearts were removed from the chest and infarct size measured from 
paraffin embedded sections stained with Masson Trichrome (Figs. IV.5C and D). We 
observed that rSTC-1 decreased the length of the ventricular infarct region (Figs. IV.5C 
and D).  Thus, STC-1 treatment results in reduced cardiac scarring and functional 
improvements of the ischemic heart.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV. 5. Recombinant stanniocalcin-1 (rSTC-1) administered intravenously improved heart function 
and reduced infarct size. NOD/scid mice were subjected to ischemic cardiac injury by permanent ligation 
of the left anterior descending coronary artery (LLDCA). At 1 hour and 24 hours after ligation, 2.0 mg/kg 
of rSTC-1 or equal volume of 0.9% sodium chloride (saline) was administered intravenously. Twenty one 
days after permanent LLDCA, NOD/scid mice were anesthetized and their left ventricular ejection fraction 
(LVEF) was evaluated. Then, mice were euthanized to collect heart tissue and assess infarct size. (A) 
Diagram showing the workflow of the cardiac injury model. (B) Each data point represents the average 
LVEF of 2 independent recordings with 3 consecutive cardiac cycles (n=3-6). (C) Representative images 
showing fibrosis in heart sections stained with Masson Trichrome. 4x magnification. Infarct size was 
measured at the ventricular midline of each section and expressed as the percent length of the fibrotic 
region relative to the ventricular midline length. (D) Each data point represents the average of ten infarct 
size measurements per heart (n=10-12). Data was analyzed using student’s t-tests (*p< 0.05, **p< 0.01). 
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IV.4. Discussion 
Macrophages and their precursor -monocytes- are among important immune 
effector cells that instruct inflammatory processes to defend against pathogens and 
promote wound healing [160]. Upon tissue injury or infection, monocytes are recruited 
to foci of inflammation and, in response to a variety of signals emanating from the 
microenvironment, differentiate into functional tissue macrophages [160,197]. Tight 
control of these processes is essential to prevent excessive inflammation and collateral 
tissue destruction. 
The glycoprotein STC-1 originally identified as a calcium regulatory hormone in 
fish [70,110] has emerged, for multiple reasons, as a candidate to modulate monocyte 
behavior and inflammatory response. First, STC-1 expression is widely distributed and 
responsive to numerous stress-inducing factors including hypoxia [128,129], oxidative 
stress, and inflammation [147,152]. We reported previously that STC-1 expression is 
upregulated in mesenchymal stem cells (MSCs) by signals from dying cells [67,185,217] 
and in response to caspase activation and inflammatory cytokines [185]. Second, STC-1 
is reported to blunt the rise in levels of mitochondrial ROS generated in stimulated 
macrophages [143] and decrease activation of the NLRP3 inflammasome [186], a 
cytosolic multiprotein complex present in myeloid cells that promotes cytokine 
maturation [61,218]. While mechanisms for the pleiotropic actions of STC-1 have not 
been entirely defined, most studies emphasize that the antioxidant property of the protein 
involves induction of UCPs and dissipation of the mitochondrial proton gradient 
[143,145,146]. 
In exploring the effects of STC-1 here, we discovered that STC-1 can potentially 
regulate inflammation by controlling monocyte phenotype independent of its effects on 
ROS. Specifically, we observed that STC-1 suppresses the PKC-dependent rise in 
monocyte expression of CD14, a myeloid cell receptor that detects indicators of ‘danger’ 
originating from pathogens or damaged tissue, and delivers these products to specific 
pro-inflammatory TLRs.  In subsequent experiments, we observed similar suppressive 
effects of STC-1 on CD14 expression in monocytes stimulated with a variety of 
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cytokines and danger signals classically associated with tissue injury.  Interestingly, the 
effects on CD14 expression in monocytes were relatively specific given that STC-1 
treatment did not alter levels of CD11b or TLR4 and promoted a moderate increase in 
expression of TLR2. 
Our immune system is designed to combat the threat of both infection and injury 
by responding to a particular set of molecular cues or patterns that are normally 
undetectable or absent.  TLRs play a major role in this process by distinguishing the 
conserved motifs of pathogens (PAMPs), and the endogenous factors released upon 
sterile tissue injury (DAMPs). There is considerable evidence that both PAMPs and 
DAMPs share many TLRs on macrophages and perpetuate inflammatory cytokine 
production [61]. There is also considerable evidence indicating that DAMP-mediated 
TLR signaling is implicated in the pathobiology of numerous inflammatory and 
autoimmune diseases [219-221]. For this reason, TLRs and factors associated with TLR 
signaling have become attractive therapeutic targets [61,195]. 
One of these factors, CD14, can be highly expressed by monocytes/macrophages 
and is heavily implicated in the behavior of these cells.  It is best known as a pattern 
recognition receptor of the innate immune system that directly interacts with bacterial 
endotoxin (LPS) to induce intracellular pro-inflammatory signaling cascades through 
TLR4. However, CD14 also recognizes peptidoglycans and products of 
apoptotic/necrotic cells such as the transcription factor HMGB1 [179].   The role of 
CD14 in disease progression has become apparent with studies revealing that CD14 
deficient mice are protected against LPS-induced cardiac inflammation [222], ischemic 
tissue injury [223], and septic shock [178]. Moreover, several studies have demonstrated 
that TLR4 inhibition with antibodies or knockout strategies is associated with cardiac 
benefits following infarction that include attenuation of myocardial inflammation and 
reduction in infarct size [224-226]. 
Together these findings here and from others support our initial observation that 
STC-1 effectively reduced cytokine production by monocytes/macrophages stimulated 
with LPS but only when the protein was applied concurrently with PMA to prevent the 
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cells from acquiring a CD14 positive phenotype. These findings also explain, at least in 
part, our observations that STC-1 treatment suppressed inflammation in the heart and 
improved cardiac function after ischemic injury by reducing levels of cardiac CD14. 
Similar to the sequence of events that accompany ischemic injury in many 
tissues, myocardial ischemia and the resulting formation of necrotic cells triggers an 
intense inflammatory reaction that is important for monocyte recruitment and tissue 
repair but when lingering can become disadvantageous for tissue function [195-197]. It 
has been shown that both DAMP/TLR and IL-1 signaling can exacerbate post-infarction 
cardiac inflammation and lead to symptoms of heart failure [195,197].  Here we showed 
that STC-1 can potentially protect the heart by reducing levels of IL-1β suggesting that it 
could be employed in therapeutic regimens for treatment of patients suffering from 
ischemic cardiac injury.  Previous studies support this concept having demonstrated that 
STC-1 inhibits ischemic injury to the kidney [227] and brain [128]. The improvements 
we noted in heart function with STC-1 treatment were also preceded by efficient 
reduction in levels of MPO, an enzyme found in neutrophils that catalyzes production of 
hypochlorous acid and other highly reactive moieties with important microbicidal 
properties [228]. However, MPO can be toxic to cells and detrimental to the remodeling 
process after myocardial infarction therefore, reduction in levels of MPO can prevent 
deterioration of cardiac tissue. Our data suggest that STC-1 treatment might reduce 
cardiac MPO through downregulation of CD14 in the heart and subsequent decrease in 
macrophage response to DAMPs that signal through CD14.  Alternatively, reduction of 
MPO in the infarcted heart could be a result of the ability for STC-1 to decrease 
permeability of vascular endothelial cells [229] and prevent migration of neutrophils. 
Regardless, STC-1 is an intriguing protein that exerts multiple beneficial effects 
in damaged mammalian tissue. Yet, the signaling pathways that drive STC-1 action have 
not been clearly defined and specific receptors that bind STC-1 have not been 
determined.  Moreover, knowledge of the distribution of STC-1 following intravenous 
administration is lacking as well as our understanding of how STC-1 might regulate 
monocyte function in vivo. Future studies are being designed to find answers to these 
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concepts.  With a recent study identifying a reservoir of splenic monocytes that are 
deployed to the infarcted heart [157], it is feasible to hypothesize that STC-1 does not 
suppress inflammation by directly binding to cardiac cells but instead associates with 
monocytes from the blood and spleen, and suppresses CD14 expression in these cell 
populations.  This hypothesis is supported by previous observations that TLR inhibition 
prevents systemic inflammation following myocardial infarction [224-226,230-232]. 
In conclusion, as shown in Figure IV.6, our data demonstrate the STC-1 regulates 
monocyte phenotype in response to a variety of differentiation stimuli and, in turn, 
suppresses levels of inflammatory factors produced by activated 
monocytes/macrophages.  Moreover, we demonstrate that STC-1 treatment effectively 
attenuates inflammation in the ischemic heart and improves cardiac function.  Our 
observations provide a novel mechanism for STC-1 action that could be important for 
tissue repair by preventing excessive inflammatory response without disrupting the 
tissue healing properties of macrophages.    
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Figure IV. 6. Summary of recombinant stanniocalcin-1 (rSTC-1) effects on monocyte/macrophage 
differentiation and function. Tissue injury induces release of differentiation stimuli (such as pathogen-
associated molecular pattern molecules (PAMPs), damage-associated molecular pattern molecules 
(DAMPs), cytokines, and chemokines) that promotes monocyte differentiation and recruitment to the site 
of injury. Differentiation stimuli cause an increase in expression of surface molecules such as CD11b and 
CD14 in monocyte/macrophage and enhance secretion of inflammatory cytokines and chemokines (for 
example TNFα, IL-1β, CXCL2, and CCL2) in these cells. Administration of rSTC-1 during differentiation 
process reduces the expression of CD14 in monocyte/macrophage, which decreases the secretion of 
inflammatory cytokines and chemokines and reduces the inflammatory response to the tissue injury. 
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CHAPTER V  
CONCLUSION 
 
Inflammation is an essential mechanism for removing infectious agents, 
protecting tissue from insults, and promoting repair in damaged organ. The usual 
outcome of the acute inflammatory action is successful elimination of infection and 
repair of tissue damage. However, failure in removing offending agents, or constant 
exposure to the irritants can lead to persistent activation of immune cells. The production 
of proteases, ROS, and growth factors by activated neutrophils and macrophages can 
cause tissue destruction. In addition, aberrant collagen formation by activated fibroblasts 
leads to excessive scarring and loss of organ function; therefore, activated immune cells 
such as monocytes/macrophages function as a double-edged sword with both offensive 
as well as defensive actions at a site of injury.  
Multipotent MSCs can respond to the microenvironment of injured tissues. The 
cells generate immune-modulatory and anti-inflammatory effects via cell-to-cell 
interaction, secretion of regulatory factors, and exosomes. The dramatic beneficial 
effects of MSCs observed in various disease models have supported their use in 
numerous clinical trials. Since MSCs have low immunogenicity with limited risks of 
tumorigenicity, their applications for allogeneic transplantation are known to be safe. 
Signals from injured tissues activate MSCs to secrete beneficial factors and contribute in 
immune/inflammatory modulation and tissue healing; however, several reports indicate 
that MSCs have a short half-life in the host [3]. Different strategies have been considered 
in order to activate MSCs prior to in vivo administration, which could eliminate the lag 
period required to upregulate expression of appropriate genes, and thus, enhance the 
therapeutic potentials of the cells. In addition, application of secreted proteins from 
MSCs has been tested as an alternative approach in different disease models.  
In the present work, the effects of 3D cultures on production of anti-
inflammatory factors by aggregated MSCs were tested. A hanging drop culture method 
was used to produce uniform MSC aggregates as spheroids in culture. Gene expression 
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and secretion of anti-inflammatory proteins such asTSG-6 and STC-1 were shown to 
increase dramatically early after incubation of the cells in the drops. Previous studies 
reported that MSCs do not secrete TSG-6 and STC-1 in standard 2D cultures; however, 
MSCs dissociated from spheroids could maintain high levels of TSG-6 and STC-1 
expression for at least one day in standard 2D culture highlighting the enhanced anti-
inflammatory potential of spheroid and spheroid derived MSCs as compared to the non-
activated MSCs. Interestingly, spheroid MSCs, cultured in the conditions optimized for 
secretion of TSG-6 and STC-1, retain the properties of MSCs from standard 2D cultures. 
The enhanced anti-inflammatory effects of spheroids and spheroid derived cells were 
further examined in a co-culture system with LPS-stimulated macrophages and a mouse 
model of zymosan-induced peritonitis. These observations suggest that the rapid anti-
inflammatory effect of spheroid MSCs reduces the early cascade of inflammatory 
responses in the host, and therefore, improve the therapeutic potential of MSCs in acute 
tissue injuries.  
Data from microarray assays demonstrated significant differences in the 
transcriptomes of spheroid MSCs compared with cells from standard 2D cultures. 
Several of these differentially expressed genes suggest potential therapeutic uses of 
spheroid MSCs, including anticancer proteins (TRAIL, IL-24, and CD82) and 
chemokine receptor CXCR4 as well as anti-inflammatory factors. Thus, while a large 
number of non-activated MSCs from 2D cultures undergo cell death during activation in 
vivo, self-activated spheroid MSCs generate a variety of beneficial factors right after 
their administration into the host. In addition, the media conditioned by spheroid MSCs 
in drops contain high concentrations of these factors and can potentially be used in 
different pathological conditions.  
In this study, local administration of spheroid MSCs was shown to reduce acute 
peritonitis in mice. MSCs have been previously demonstrated to reduce inflammation 
and tissue injuries from distance site in a number of mouse models, including 
myocardial infarction and cornea injury [51,64]. Therefore, intraperitoneal 
administration of intact spheroid can also be used for systemic modulation of 
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immune/inflammatory responses. Another potential therapeutic advantage of spheroid 
MSCs was their size.  MSCs dissociated from spheroids were about one/forth the 
volume of 2D cultured MSCs, and thus, larger numbers of these cells could pass through 
pulmonary microvasculature and home to other tissues. Together these results suggest 
that intact spheroids and spheroid derived MSCs may have major advantages for 
different strategies of MSC administration.   
Spheroid MSCs are in close contact with each other comparable as they are in 
vivo. In addition, the cells experience nutrient deprivation, air-liquid interface, and 
microgravity. These factors alter the microenvironment in hanging drops and could lead 
to activation of MSCs in spheroids. Bartosh and colleagues have demonstrated recently 
that caspase-dependent IL-1 signaling, activated by aggregated MSCs in hanging drops, 
was required for upregulation of TSG-6, STC-1, and another potent anti-inflammatory 
factor PGE2 in MSCs [185]. Since the cells can produce similar aggregates in vivo, these 
results can explain, at least in part, the beneficial effects of MSCs in animal models. 
More detailed studies can help identify the key factors for self-activation of MSCs in 
vitro and in vivo in order to optimize culture conditions for different therapeutic 
potentials of the cells. Meanwhile, the hanging drop method can be used to produce 
MSCs with enhanced therapeutic potential for different diseases; therefore, it is essential 
to determine any loss of activity in freshly thawed cells from frozen cell banks to 
evaluate the clinical applications of spheroids and spheroid derived MSCs.  
Previous studies have shown that STC-1 produces some of the beneficial effects 
of MSCs in vitro and in vivo. This protein can protect injured tissues by reducing the 
generation of ROS, apoptosis, and immune/inflammatory response, and thereby, its 
therapeutic potential has been considered for various diseases.  
In the present work, the effects of STC-1 on stimulated monocytes/macrophages 
were studied. Monocytes differentiate to pro-inflammatory macrophages in the early 
stages of tissue damage and play important roles in immune/inflammatory actions. 
Administration of recombinant human STC-1 concurrent with monocyte-to-macrophage 
differentiation was shown to suppress the secretion of inflammatory mediators (TNFα, 
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CCL2, and CXCL2) by differentiated cells in response to LPS in vitro; however, 
treatment with this protein after maturation of monocytes/macrophages did not have any 
significant effects on their inflammatory actions. Therefore, the distinct characteristics of 
the differentiating monocytes/macrophages in the presence or absence of STC-1 were 
tested. Treatment with STC-1 was shown to reduce the expression of TLR4 co-receptor 
CD14 in monocytes/macrophages stimulated with both PMA and various endogenous 
danger signals, whereas there were no significant differences in the expression of TLR4 
or monocyte/macrophage marker CD11b. In contrast, the expression of TLR2 was 
increased. These observations suggest that STC-1 can modulate inflammatory responses 
of stimulated monocytes/macrophages by regulating the expression of CD14.  
CD14 is predominantly expressed by myeloid cells. This TLR co-receptor plays 
major roles in recognition and responses of immune cells to numerous PAMPs and 
DAMPs [176,177,179]. In addition, the involvement of CD14 in progression of different 
diseases such as cardiac inflammation has been demonstrated recently [178,222,223]; 
Although little is known about the factors controlling the expression of CD14 on 
monocytes/macrophages, a number of factors have been reported to reduce the 
transcription of CD14 such as IL-4 [233]. Therefore, it would be of interest to determine 
the correlation between STC-1 and expression level of these factors, especially IL-4, in 
differentiating monocytes/macrophages.  
Also, mechanisms for the pleiotropic actions of STC-1 have not been entirely 
defined; nevertheless, the expression of mammalian STC-1 is responsive to numerous 
stress-inducing factors. The protein has been identified to modulate the calcium influx, 
which suggests its regulatory role on the calcium-dependent signaling pathways; 
therefore, in order to determine the key factors involved in inhibition of CD14 
expression, differentiation assay could be performed in the presence or absence of 
calcium channel blockers. The downregulation of CD14 in differentiating 
monocytes/macrophages blocked for calcium entry would suggest the mechanisms for 
STC-1 action on modulation of CD14 expression. This hypothesis could be further tested 
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to demonstrate STC-1 binding to the calcium channels in stimulated 
monocytes/macrophages using immunoprecipitation assay.  
In addition, STC-1 has been shown to suppress generation of mitochondrial ROS, 
at least in part, by upregulation of UCPs. To identify the role of UCPs in expression of 
CD14, first the mRNA levels of UCP2 should be determined in differentiating 
monocytes/macrophages. If STC-1 treatment results in upregulation of UCP2, small 
interfering RNA (siRNA) could be used to suppress the expression of this protein in 
monocytes prior to differentiation assay. The upregulation of CD14 in UCP2 knocked-
down cells, despite presence or absence of STC-1, would suggest an UCP-dependent 
controlling mechanism for CD14 expression in myeloid cells.  
  Interestingly in the current study, i.v. administration of STC-1 decreased the 
amount of CD14 in the hearts of mice after LLDCA. CD14 is expressed in other immune 
cells as well as non-immune cells, which makes it difficult to assume that STC-1 therapy 
reduced the expression of CD14 only in monocytes/macrophages. Detailed studies, 
including immunostaining for co-expression of CD14 and monocyte/macrophage 
markers in the heart sections as well as flow cytometry of immune cells isolated from 
blood and spleen of healthy and injured animals would lead to better understand anti-
inflammatory and immune modulatory potentials of STC-1.  
STC-1 also reduced the amount of cardiac IL-1β and MPO. Mature form of IL-
1β is involved in a wide range of immune/inflammatory responses and can exacerbate 
post-infarction cardiac injury [197]. Excessive MPO can be toxic to cardiomyocytes and 
deteriorate ventricular remodeling; therefore, STC-1 can protect cardiomyocytes and 
prevent heart failure by reducing these inflammatory mediators. Since STC-1 
administration reduced the amount of CD14 in the heart, it can be suggested that 
decreased sensitivity of monocytes/macrophages to DAMPs can result in reduction of 
these mediators. STC-1 has been previously shown to decrease permeability of vascular 
endothelial cells and prevent migration of immune cells [148,229]; thus it can also be 
suggested that STC-1 inhibits cardiac inflammation by reducing the migration of 
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immune cells to the site of injury. This hypothesis could be examined by counting the 
number of infiltrated cells to the heart in the sections.  
Long-term evaluation of experimental mice demonstrated that cardiac function 
and infarct size were improved three weeks after STC-1 treatment. CD14 deficiency has 
been shown to protect CD14 knockout mice against LPS-induced cardiac inflammation 
and ischemic tissue injury [222,223]; therefore, it can be assumed that STC-1 protects 
heart from excessive inflammation and supports tissue repair by a novel mechanism to 
control monocyte/macrophage functions. 
In conclusion, the current study demonstrates that self-activated MSCs in 
spheroids provide enhanced therapeutic potential for the clinical use of the cells. Also, 
this study reveals a novel mechanism for STC-1 and promotes the potential therapeutic 
use of STC-1 for tissue injury. 
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